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Abstract

Humans consider themselves discrete autonomous organisms, but recent research is rapidly strengthening the appreciation that associated
microorganisms make essential contributions to human health and well being. Each person is inhabited and also surrounded by his/her own
signature microbial cloud. A low diversity of microorganisms is associated with a plethora of diseases, including allergy, diabetes, obesity, arthritis, inflammatory bowel diseases, and even neuropsychiatric disorders. Thus, an interaction of microorganisms with the host immune system is required for a healthy body. Exposure to microorganisms from the moment we are born and appropriate microbiome assembly during childhood are essential for establishing an active immune system necessary to prevent disease later in life. Exposure to microorganisms
educates the immune system, induces adaptive immunity, and initiates memory B and T cells that are essential to combat various pathogens. The correct microbial-based education of immune cells may be critical in preventing the development of autoimmune diseases and
cancer. This review provides a broad overview of the importance of the host microbiome and accumulating knowledge of how it regulates
and maintains a healthy human system.

Role of the Microbiome in Maintaining Host
Health

gut, skin, and oral cavity. The microbiota of our system is well tolerated by our immune system due to the coevolution of these microorganisms over time. The overwhelming majority of gut microbiota are Eubacteria. The collective genome, or metagenome,
of the enteric microbiota contains over 100 times the number of
genes in the human genome, and there are approximately 10-fold
more genes in each of our microbiomes than in each of us, encoding the greatest source of potential antigens with which the
immune system must cope (6). The microbiome in humans significantly enriches the metabolism of glycans, amino acids, and xenobiotics. It is also responsible for the synthesis of vitamins, isoprenoids, and other nutrients, making humans “superorganisms”
whose metabolism represents an amalgamation of microbial and
human attributes (7).
Each individual emits a distinct and personalized cloud of microorganisms into his or her surroundings (8). The microbiome in
humans is also not constant during lifespan, but rather changes
with age. Culture and location also have a profound impact on

At all stages of life, humans are associated with microorganisms and their products. Humans coevolved with microbes in the
environment, and each body habitat has a unique set of microorganisms in its microbiota (1). The microbiome (term coined by
Joshua Lederberg) consists of the ecological community of commensal, symbiotic, and pathogenic microorganisms that share our
body (2). The host organism together with its microbiome constitutes the “holobiont” (Greek, holos, whole/entire), and the totality
of the genome is the “hologenome” (3, 4). Changes in the holobiont may impact the complex signaling network, thereby influencing the hologenome leading to health or disease.
The human body is estimated to be composed of 3 × 1013 eukaryotic cells and 3.9 × 1013 colonizing microorganisms, such that
host cells and microbiota are of nearly the same number in an individual (5). The largest concentrations of microbes occupy the
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the microbiome (9). Health status is yet another factor influencing the microbiome compositional status. In one study, the growth
dynamics of gut microbiota in health and disease have been inferred from a single metagenomic sample (10). These authors copy
the number and ratio at origin and terminus to detect the actively
growing species in a microbiome. In this way, they showed differences between virulent and avirulent strains, population diurnal oscillations, and bacterial species predominant during disease
and diet changes.
Diet is a particularly important factor in determining the microbiota composition of the gut (11). Thus, vegans, vegetarians,
and omnivores have distinct microbiomes. Total counts of Bacteroides spp., Bifidobacterium spp., Escherichia coli (E. coli), and Enterobacteriaceae spp. were significantly lower in vegan samples
than in controls. In contrast, total counts of Klebsiella spp., Enterobacter spp., other Enterobacteriaceae, Enterococcus spp., Lactobacillus spp., Citrobacter spp., and Clostridium spp. were similar in
people with different diets. Subjects on a vegetarian diet ranked
between vegans and omnivores. The total microbial count did not
differ between the dietary groups (12). Notably, the microbiome of
a person can be altered rapidly by changes in dietary patterns. It
has been demonstrated by David and colleagues (13) that shortterm consumption of diets composed entirely of animal or plant
products can alter the microbial community structure. An animalbased diet increased the abundance of bile-tolerant microorganisms, including Alistipes, Bilophila, and Bacteroides and decreased
the levels of Firmicutes that metabolize dietary plant polysaccharides (Roseburia spp, Eubacterium rectale, and Ruminococcus bromii). Thus, the gut microbiome rapidly responds to diet.

Microbiome Taxonomy and Its Future

The taxonomy of microbiomes reflects their complexity and the
challenges encountered in their understanding. Microbiomes include species across all major kingdoms, including viruses as well
as Archaea, bacteria, and microbial eukaryotes. Our current depth
of knowledge is associated with different methods of investigation, targeted surveys, and scope of studies conducted. To date,
the most comprehensively investigated phylogenic group in health
and disease has been bacteria.
Prokaryotes
List of Prokaryotic Names with Standing in Nomenclature
(http://www.bacterio.net) includes two prokaryotic domains (or
empires), subdivided into 30 phyla in the domain Bacteria and 5
phyla in the domain Archaea. Together, these 35 phyla encompass
about 2,400 genera and 12,400 species (14). This list is based on
strict requirements, including the availability of reference strains,
and does not include all available reference strains deposited
in culture collections, including the ones for which genome sequences are already available (15–17). The addition of whole-genome phylogenetic analysis allows a refined positioning in the
phylogenetic hierarchy as new tools are being developed (18–21).
This approach brings some conflicts with the current classification,
as has happened when the 16S rRNA gene phylogenetic classification competed with the phenotypic classification (22–24). In addition, the ability to target and obtain the sequence of the genes
used for phylogenetic classification (16S rRNA, recA, rpoB, gyrB,
etc.) using culture-independent methods also adds to the known
diversity. Specialized curated databases that allow the propagation of this knowledge include SILVA, Ribosomal Database Project,
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and the Human Oral Microbiome Database (23, 25, 26). This culture-independent approach raised to 46 the number of phyla (23).
How much of this diversity is in the human microbiome is unclear.
However, it is already clear that organisms known to be environmental are also associated with health and that at least 30 prokaryotic phyla and 950 genera are associated with the human microbiome (27, 28).
Microbial eukaryotes
The microbial eukaryotes are extremely diverse and do not fit
under a single keyword. Although accurate, the eukaryotic supergroups defined by phylogenomics [Opisthokonta, Amoebozoa,
Excavata, Archaeplastida, and SAR (Stramenopiles + Alveolates +
Rhizaria)] are unfortunately uninformative compared with previous
classification methods used in the literature. From the clinician to
the lay person, terms such as fungi, protists, parasites, protozoa,
and amoebae are much more familiar. In this area, current knowledge is based mostly on their roles as causative agents of disease;
few studies have focused on healthy individuals or within a defined
illness in a restricted number of individuals (29–33). Until recently,
the focus on single disease agents also meant neglecting the remainder of the eukaryotic microbiome (34, 35).
The human eukaryotic microbiome includes pathogens, commensals, and beneficial organisms. The fungi (Opisthokonta) harbor a wide diversity of organisms, with an overlap for the skin
with the local environment (35). The fungi include the Ascomycota
(Candida albicans), Basidiomycota (Cryptococcus neoformans), Microsporida (Encephalitozoon intestinalis), and Zygomycota (Rhizopus microsporus). As fungi are part of the environment and human
alimentation, it may be difficult to differentiate between transient
and commensal organisms without a longitudinal study, unless a
disease or an opportunistic infection occurs (36, 37). The Acanthocephala, most closely related to the rotifers, include Macracanthorhynchus hirudinaceus. The helminths (Opisthokonta), which are
classified as part of the animals, include the cestodes (tapeworms,
Taenia saginata), trematodes (flukes, Schistosoma mansoni), and
nematodes (roundworms, Enterobius vermicularis). Although the
majority of the helminths cause illness in millions of people worldwide, a few helminth species have been used in therapy (38, 39).
The protozoa include the Amoebozoa (Amoebozoa; amoeba: Entamoeba histolytica), Metamonada (Excavata; flagellates: Giardia intestinalis), Parabasilia (Excavata; Dientamoeba fragilis), Ciliophora
(SAR; ciliates: Ballentidium coli), Apicomplexa (SAR; Cryptosporidium parvum), and Stramenopile (SAR; Blastocystis hominis). These
protozoa are all medically important even though not all carriers
are symptomatic (30, 35). The Archaeplastida (including green and
red algae) can be present in the microbiome of the skin and digestive tract. Additional sequences available through the sequencing
of targeted genes, including via metagenomics, have expanded
this knowledge and are maintained and curated in databases such
as SILVA (23). A current view of the tree of life, encompassing the
total diversity represented by sequenced genomes, was published
recently by Hug and colleagues (40).
Viruses
The gut microbiome includes bacteriophages that influence the
bacterial hosts. The bacteriophage in the human gut are of three
classes: a set of core bacteriophages shared among more than half
of the human population, a common set of bacteriophages found
in 20% to 50% of individuals, and a set of bacteriophages that are
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unique to a person. Healthy gut phageome (aggregate of bacteriophage in the gut) is significantly decreased in individuals with
gastrointestinal diseases (41). The International Committee on Taxonomy of Viruses in its 2014 release listed 104 families, 505 genera, and 3,186 species of all known viruses (42). The human virome
overlaps with other animal viromes. These dsDNA, ssDNA, dsRNA,
ssRNA– ssRNA+ viruses, and dsDNA and ssRNA retroviruses can
affect any of the tissues within the body. Human protists (nonfungal microbial eukaryotes) have their own viral challenges, which
are being uncovered within the human virome (43). Much more
is known about mycoviruses and their intracellular transmission
during cell division and sporogenesis, and it is recognized that
their life cycles generally lack an extracellular phase. Most known
mycoviruses have dsRNA genome, but an increasing number of
positive- or negative-strand ssRNA and ssDNA viruses have been
isolated and characterized (44). Most of the archaeal viruses have
been isolated from members of the Euryarchaeota and Crenarchaeota with broader morphologic characteristics than their bacterial counterpart (45). Little is known of the impact of archaeal
viruses on the human virome. The dsDNA, ssDNA, dsRNA, and ssRNA bacteriophages have a great impact on prokaryotic ecology
through their ability to modify population structure. A list of viral pathogens is maintained by the ViPR resource, whereas prophages are available at PHAST (46, 47).
Future of taxonomy
An open challenge in taxonomy is to refine the classifications
to be more compatible with the emerging methods of molecular
biosurveillance and detection, requiring targets associated to an
outcome or being able to identify strains at multiple body-sites
across the domains of life (21, 48). This work is dependent on a
greater understanding of the true diversity in the population with
the direct sequencing of large sample sets and/or large cohorts,
such as the Human Microbiome Project, MetaHIT, BioMarks, and
future large-scale projects (49–51). New resources are now attempting to bridge the different approaches and topics of detection across domains, such as the Human Pan-Microbe Community database (34). The ability to isolate and sequence single cells
offers the opportunity to deepen both our understanding of the
genomic composition of taxonomic diversity, as well to put this
diversity in context of its environment, microbial partners, biogeography, and host physiologic status both at the local and systemic levels (52–54).
Beyond this time, taxonomy and the species level classification
focused on vertical transmission of conserved information to descendant cells. The strain definition is associated with gene composition and gene modification, including mutations and antigenic
variation following homologous DNA recombination, CRISPR system (clustered regularly interspaced short palindromic repeats),
gene transfer, mobile elements, epigenetics, etc. Moving from
targeted gene phylogeny to whole-genome comparison has its
own limitations that can be complemented by the inclusion of
other omics as once metabolic panels, protein, and DNA fingerprinting profiles were used. This polyphasic analysis allows understanding genetic relatedness and phylogenic relationship in
the context of disease, reservoir, niche transmission within a single individual, propagation within a population, and dissemination among environments. An increasing number of gene transfer events among domains is being documented as well as across
ecological niches (55–57). The genetic modification can be due
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to increases in genetic content, but genetic loss also has critical
consequences in competitiveness or niche settlement (58, 59). As
no clear general phylogenetic definition of strain has emerged in
this era of genomics, efforts are to differentiate the different isolates with markers not yet found in other genomes and/or SNP
(20, 21, 60, 61).

The Infant Microbiome and Transgeneration
Effects
Until recently, the placenta was considered a “sterile” intrauterine environment. Aagaard and colleagues (62) reported that the
placental microbiome is consistently different from other parts
of the body, including the skin and urogenital tract. Interestingly,
the placental microbiome is most similar to that of the oral cavity. Thus, these authors suggested that microbes travel to the placenta from the mouth via blood. The results reinforce data that
have suggested a link between periodontal disease in the mother
and the risk of preterm birth.
Infant-associated microbial communities initially possess high
concentrations of facultative anaerobes, such as E. coli and Streptococcus spp., but these populations are replaced by strict anaerobes coinciding with a reduction in oxygen tension (63–65). In addition to environmental routes of inoculation, the specific mode by
which the infant is delivered is now known to influence the early
gut microbiome structure and trajectory.
Although there is emerging evidence that the fetus encounters
placental and amniotic bacteria in utero, it is clear that parturition
contributes to the infant’s first major inoculation of colonizing microbes (63, 66, 67). Microbial communities colonize external surfaces of the infant immediately following birth. This includes various microbial populations that are established and maintained
along the gastrointestinal tract. The percentage of babies delivered through cesarean section (C-section) has risen in many countries. Although a number of C-section deliveries are performed
for obstetrical indications, a large proportion is not medically indicated and may be due to maternal request and may incur several risks for the child (68). Obstetricians in many medical settings
are paid more for cesarean delivery, and it is well known that private hospitals and practitioners encourage cesarean delivery (69).
However, recent studies demonstrated that babies born vaginally
are healthier compared with babies born by cesarean delivery. As
such, infants delivered vaginally tend to harbor microbiotas that
are typically encountered in the female reproductive tract, such
as Lactobacillus. In contrast, cesarean delivery is typically associated with Staphylococcus spp. and other bacteria that are associated with the mother’s skin and hospital environment (65, 70, 71).
Children delivered by C-section have significantly increased risk
of asthma, systemic connective tissue disorders, juvenile arthritis,
inflammatory bowel disease, immune deficiencies, leukemia (72),
and Crohn disease (73). Although there are some indications that
infants born via C-section may be more susceptible to colonization
by Clostridium difficile (C. difficile) or methicillin-resistant Staphylococcus aureus (S. aureus), and may be at an increased risk for
pathologies later in life (71, 72), additional mechanistic studies are
required to conclude causal relationships in this regard.
The infant microbiome exhibits several shared attributes regardless of birth method. In general, the infant microbiome is
often dominated by the genera Bifidobacterium, Bacteroidetes,
and members of clostridial taxa (74). In the seminal 2012 study
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conducted by Yatsunenko and colleagues (9), gut microbiomes
were characterized from individuals located in three distinct geographic locations (i.e., United States, rural Malawi, and rural Venezuela). Regardless of the host’s location, microbial populations
converge toward an adult community by 3 years of age (9). Furthermore, microbial community diversity increased as the host
aged across all populations (9). Infant microbiomes exhibit hallmarks of functional redundancy, in that interindividual taxonomic
variation is common despite sharing a stable and uniform metabolic potential (75). This functional redundancy during neonatal development may contribute to metabolic, digestive, and immune system homeostasis (74, 76). During infancy, the impact of
alterations in community assembly on function has been linked
to outcomes such as malnourishment, C. difficile–associated diarrhea, and necrotizing enterocolitis (74, 76, 77). Early-life microbiome disruption may potentially increase risk for developing celiac disease, asthma, type I diabetes, and obesity (70, 72, 78–81).
These conditions could have long-term medical implications that
interact reciprocally with the gut microbiome.
Perturbations or durable disruptions of the infant microbiome
may proceed via several paths, with hospitalization and antibiotic
use considered to be primary causes. Preterm and term infants
who are hospitalized early in life are at a greater risk for nosocomial C. difficile infection (74, 82). Thus, the hospital environment
is a reservoir for infectious agents that may be deleterious for atrisk populations, such as preterm infants with underdeveloped
immunologic function. As antibiotics select for resistant and resilient strains, indiscriminant usage of antimicrobials may drive gut
dysbiosis in certain instances. Several studies have characterized
the influence of antibiotic usage on restricting gut microbiota diversity, potentially increasing susceptibility to aggressive bacterial infections like C. difficile and vancomycin-resistant Enterococcus bacteremia (82–84).
As it does in adults, diet exerts a strong influence on the structural composition of infant-hosted microbiomes. Culture-dependent and independent studies indicate that breastfed infants often
possess a significantly different and less diverse gut microbiome
relative to formula-fed infants (9, 64, 85–87). Accordingly, human
milk incorporates several bioactive compounds important for infant nutrition, including lipids, proteins, and lactose. In addition,
several milk molecules enhance immunologic and neurologic development (88–90). Escaping digestion by host glycosyl hydrolases,
soluble milk glycans are transferred to the distal colon, where they
are exposed to the gut microbiota of the infant. Thus, these human
milk oligosaccharides (HMO) are available to guide the establishment and function of the infant microbiome. HMOs are heterogeneous carbohydrate polymers that are the third most abundant
milk component at several grams per liter (91). HMO structures incorporate the monosaccharides d-glucose, d-galactose, N-acetylglucosamine, l-fucose, and N-acetylneuraminic acid, with more
than 200 unique HMO isomers composed of these components
identified to date (91, 92).
Breastfeeding infants often display a microbiome enriched for
commensal Bifidobacteria that can utilize HMOs. Bifidobacteria
are Gram-positive anaerobes of the phylum Actinobacteria, which
typically colonize infants and adults to a lesser degree (93–95).
Accordingly, Bifidobacterium longum (B. longum) subsp. infantis
is a major commensal of breastfed infants, with this lineage possessing a large genomic cluster that enables HMO utilization (95).
That unique gene assemblage permits the catabolism of specific
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small mass HMOs that other Bifidobacteria cannot process. For
example, in comparison with other Bifidobacteria, B. longum
subsp. infantis flourishes in the presence of milk that contains
α1,2-fucosylated HMOs (96). An individual’s complement of HMO
structures is somewhat dependent on the mother’s genotype and
may vary by gestational age and stage of lactation. The relative
concentrations of α1,2-linked fucosyl moieties depend on the fucosyltransferase 2 allele (96). Women with a functional copy of
this gene, termed secretors, may confer certain health benefits to
their infant such as a decreased risk for diarrheal diseases (96–98).
HMOs can decrease the presence of gastrointestinal pathogens
using two primary mechanisms. HMOs themselves mimic pathogen-binding sites of receptors that decorate the surface of host
cells (99–101). Studies have documented this effect using Vibrio
cholerae, Streptococcus pnemoniae, and E. coli (102–104). In addition, high levels of Bifidobacteria are correlated with lower incidence of potentially dangerous neonatal infections, potentially
due to competitive exclusion (105, 106). Gut microbiota development during infancy can have long-lasting effects on the individual’s future health. Colonization of fucosyllactose-utilizing Bifidobacteria is due to an ABC transporter that acts as a key genetic
factor for fucosyllactose utilization (107).
Human milk is generally accepted as the best nutrition for newborns and has been shown to support the optimal growth and development of infants (108). Human milk also provides bioactive
components that are important to optimize gut microbial colonization, immune maturation, metabolic development, and even
cognitive development. Breast milk has a low buffering capacity, which would make the gut more susceptible to a lowering of
pH due to acid production from bacterial fermentation in the colon. The fecal pH of the breastfed infant is between 5 and 6 dominated by Bifidobacteria, whereas formula-fed infants have a fecal
pH in the range of 8 to 9. The acetic acid in the gut of breastfed infants is frequently present as an acetate buffer. This effect
was not observed in formula-fed infants. The lower pH in the gut
is an important factor in restricting the growth of Enterobacteria, Clostridia, and the Bacteroides and favors the proliferation
of the acid-tolerant Bifidobacteria and Lactobacilli (109). Human
milk also contains many antimicrobial factors, such as partially
digested or fermented peptides, milk-borne fatty acids, human
lactoferrin, lysozyme, and secretory IgA. These factors may decrease the prevalence of pathogens in the gut’s ecosystem in infants. The broad range of nondigestible oligosaccharides specifically found in human milk but not in other mammals’ milk (108) is
a major factor in the prevention of pathogen growth in the gastrointestinal tract. Stunted infants fed poorly have low amounts of
sialylated HMOs in the gut. These oligosaccharides are not used
by the body, but rather used by the gut microbes. Charbonneau
and colleagues (110) colonized germ-free mice with a consortium of bacterial strains cultured from the fecal microbiota of a
6-month-old stunted infant and fed recipient animals with normal diet with or without purified sialylated bovine milk oligosaccharides (S-BMO). S-BMO produced a microbiota-dependent body
weight gain, indicating growth promotion in the presence of gut
microbiota. However, control animals that were germ free did not
increase body weight, demonstrating some bacteria in the gut are
involved in weight gain.
Infant formula is often based on bovine milk unless it is plant
derived. Fluid dairy milk contains oligosaccharides with a similar structure to HMOs, which may suggest similar functionality
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despite being incorporated at relatively low concentrations (108,
111–113). At the moment, there are efforts to supplement infant
formula with oligosaccharides, although HMO structures are difficult to synthesize and may not be commercially viable (114).
However, oligosaccharides from other sources may increase bifidobacterial concentration as a preferred endpoint, including galacto-oligosaccharides and fructo-oligosaccharides.
Use of oral probiotics by the mother during pregnancy is
thought to help the developing baby. Microbes in the placenta or
amniotic fluid affect fetal innate immune gene expression during
late pregnancy. Maternal probiotic supplementation significantly
modulated the expression of Toll-like receptor (TLR)- related genes
both in the placenta and in the fetal gut. Thus, fetal and placental
immune physiology may be modulated by maternal dietary interventions, including using specific probiotics (115, 116). It has also
been shown that maternal probiotic supplementation during pregnancy and breastfeeding reduces the risk of eczema in the infant
(116). Probiotic supplements continue to impact infants in their
early years. It has been shown that infant formula supplemented
with the probiotics Lactobacillus rhamnosus (L. rhamnosus) GG and
Bifidobacterium lactis Bb-12 offers a safe means of reducing the
risk of early acute otitis media and antibiotic use and the risk of recurrent respiratory infections during the first year of life (117). Probiotics enhance gut-specific IgA responses, which are frequently
defective in children with food allergy (118). Kainonen and colleagues (119) have demonstrated that exclusive breastfeeding promotes an anti-inflammatory cytokine milieu, which is maintained
throughout infancy. Such an immunologic environment limits hyperresponsiveness and promotes tolerization, thereby prohibiting
the onset of allergic disease.
Infantile colic (excessive crying) is a common problem in about
20% of healthy thriving infants in the first 3 months of life (120).
The risk factors associated with the development of infantile colic
include maternal smoking, increased maternal age, and firstborn
status. Infantile colic could also be related to cow’s-milk protein
allergy and atopy (121). Several studies have demonstrated that
administration of probiotics containing Lactobacillus reuteri (L. reuteri) DSM 17938 significantly improved colic symptoms by reducing crying and fussing times in breastfed infants with colic (122,
123). Treatment of colic with L. reuteri did not affect the global
composition of the microbiota. The decrease in colicky symptoms
was linked to changes in the microbiota, with a relative increased
abundance of the phyla Bacteroidetes and genus Bacteroides after treatment with L. reuteri (124).

Microbiome and Aging
As humans age, the composition of the microbiome also
changes (9). Aging is accompanied by the onset of a myriad of
clinical changes, including a basal proinflammatory state (“inflamm-aging”) that directly interfaces with the microbiota of older
adults and enhances their susceptibility to diseases that accompany aging. Studies in older adults demonstrate that the gut microbiota correlates with diet, basal level of inflammation, and location of residence (e.g., community dwelling, long-term care
settings; refs. 125–127). Links between the microbiota and a variety of clinical problems plaguing older adults have been made,
including physical frailty, C. difficile, colitis, vulvovaginal atrophy,
colorectal carcinoma, and atherosclerotic disease (128).
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The most drastic change associated with the aging gut is a
change in the relative proportion of organisms, for example, Firmicutes dominate in the young and Bacteroidetes in the elderly.
Reduction in the diversity of bacteria comprising subpopulations
is seen in individuals with high frailty, although living in a community undermines this alteration (125, 129).
Aging-associated oxidative stress induces aggressive potential and virulence factors of anaerobic bacteria, thereby causing
morphologic alterations of bacterial cells that could impact the
host. The microbiota may also influence host gene expression by
regulating miRNAs (130). Analysis of the network functions revealed that differentially regulated miRNAs between infants and
adults and miRNAs that decreased during aging shared two network functions: inflammatory disease and inflammatory response.
miRNAs promote aging by modulating their targets to drive cell
senescence and aging in different tissues or organs. There is significant variation in the expression of miRNA during aging. Genome-wide assessment of miRNA expression revealed that the
majority of miRNAs decreased with age (131, 132). Interestingly,
host-derived miRNAs may also influence the composition of the
gut microbiome (133).
It has been documented that calorie restriction can increase the
life span of model organisms (134). Notably, Zhang and colleagues
(135) demonstrated that calorie restriction enriches bacterial phylotypes positively correlated with lifespan. Bacteria of the genus
Lactobacillus have been shown to increase in animals on low-fat
diet, and this environment reduces phylotypes that are negatively
correlated with lifespan. Caloric restriction– induced changes in
the gut microbiota occur concomitantly with a significant reduction in serum levels of lipopolysaccharide (LPS)-binding protein,
suggesting that animals undergoing calorie restriction establish a
structurally balanced architecture of gut microbiota that exerts a
health benefit through the reduction of antigen load from the gut.
Strikingly, dietary changes can detectibly influence host environment in as little as 24 hours, with longer term changes correlating
with novel enterotype clustering in the host (136).
Multiple studies in centenarians indicate extreme aging is
characterized by microbial changes deemed unique from other
age groups, with emphasis placed on organismal composition
and increased inflammatory effects (137, 138). Fecal sampling
by Rampelli and colleagues (138) revealed a distinctive functional profile with a decrease in short-chain fatty acid (SCFA)
production and saccharolytic potential but an increase in proteolytic potential. A total of 116 microbial genes were found to
be correlated with aging, including those essential to the metabolism of tryptophan, phenylalanine, tyrosine, valine, and lysine. Implications of such variability include changes in well being, aging, and disease susceptibility. This was accompanied by
an increase in the occurrence of pathobionts, bacteria usually
present in low numbers in adults. Proinflammatory effects of
the pathobionts are exaggerated by a decrease in Faecalibacterium prausnitzii (F. prausnitzii), a species associated with antiinflammatory influences (137).
The relationship between aging and the microbiome is not
strictly one-sided; it has been demonstrated that host aging can
actually be impacted by interspecies communication. Animal fecundity, development time, and lifespan were all dependent on the
amount and type of bacteria they were fed. There are multiple lines
of evidence demonstrating the ability of microbes to substantially
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change host physiology, as it pertains to these parameters (139).
Accordingly, manipulating the microbiome of older adults holds
promise as an innovative strategy to positively influence the development of comorbidities associated with aging (128).
Rozsa and colleagues (140) recently proposed the “microbiome
mutiny hypothesis,” whereby some microorganisms of the microbiome could switch to higher virulence (microbiome mutiny) in
old or seriously ill people, to optimize their transmission under
the conditions of increased background mortality. This proposed
virulence shift might contribute to the death of old or seriously ill
people even in the absence of apparent disease.
In the central nervous system (CNS), polyphenols present in
many edible plants exert anti-inflammatory effects (141) and
act on the brain in several ways. Like antioxidant vitamins, dietary polyphenols contribute to the regulation of oxidative stress
and improve vascular health. Notably, intestinal microbiotas convert dietary polyphenols to phenolic acids, stimulating the proliferation of Bifidobacteria and decreasing the ratio of Firmicutes
to Bacteroidetes, relative to controls. Polyphenols also stimulate
SCFA production by bacteria (142). Wang and colleagues (143) recently reported that the microbiome can convert grape-derived
polyphenol to the phenolic acids, 3-hydroxybenzoic acid and
3-(3ʹ-hydroxyphenyl)propionic acid, which interfere with the assembly of β-amyloid peptides into neurotoxic β-amyloid aggregates that play key roles in the pathogenesis of Alzheimer disease.
Thus, in the brain and other tissues, many healthful effects of polyphenols may relate to their conversion to various metabolic derivatives by the gut microbiome while aging.

Microorganisms and Immune Function
Through coevolution with their hosts, microbes exert a major
influence in shaping the development of the immune system, putting it under selective pressure to develop the capability to discern between invasive pathogens that it is imperative to control
and commensal resident microbes that are beneficial to tolerate
(144, 145). Many developmental aspects of the adaptive immune
system are influenced by the composition of bacterial colonization
of the gut. Thus, the mammalian immune system, which is tasked
with the duty of controlling microorganisms, is in turn fundamentally shaped by microorganisms (146). For example, it has been
demonstrated that changes to the symbiotic microbiota early in
life, or the absence of it, can lead to exacerbated type II immunity and allergies due to aberrant immune functionality. The microbiota is a strong inducer of proinflammatory Th17 cells and
regulatory T cells (Treg) in the intestine. The microbiota-induced
Tregs express the nuclear hormone receptor RORγt and differentiate along a pathway that also leads to Th17 cells. In the absence of RORγt+ Tregs, Th2-driven defense against helminths is
more efficient, whereas Th2-associated pathology is exacerbated.
Thus, the microbiota regulate type II responses through the induction of type III RORγt+ Tregs and Th17 cells, thereby balancing immune responses at mucosal surfaces (147). Exercise can also
influence the immune system and how they modulate microorganisms (148, 149). Intense exercise causes immunosuppression,
whereas moderate-intensity exercise improves immune function
and potentially reduces risk and severity of respiratory viral infection by increasing stress hormones, reduce excessive local inflammation, and skew the immune response to a Th2 phenotype (148).
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Similarly, exercise can also influence bacterial infections. Pape and
colleagues (150) demonstrated a reduction of bacterial infection
in people with physical activity compared with those that maintain a sedentary lifestyle.
Similar to adaptive immunity, the innate immunity is also influenced by the microbiome. One example of this is neutrophil aging.
Aged neutrophils exhibit impaired migration and reduced proinflammatory properties. Microbiota influence neutrophil aging via
TLR- and MyD88-mediated signaling pathways. Depletion of the
microbiota significantly reduces circulating numbers of aged neutrophils and improves pathogenesis and inflammation-related organ damage in models of sickle cell disease or endotoxin- induced
septic shock. Thus, host microbiota may play a role in regulating a
disease-promoting neutrophil subset that promotes tissue injury
in various inflammatory diseases (151).
Although active immunity is essential to combat infection, inadequate control over immune responsiveness due to the inability
to establish immune tolerance can also have dire consequences,
regardless of whether the response is directed against a foreign
pathogen or self. Meanwhile, one of the major benefits of immune
tolerance is the ability to maintain a commensal microbiome consisting of a multitude of foreign microorganisms. Thus, the mechanisms for establishing tolerance are a vital aspect of the immunoregulatory framework. One crucial element in instructing the
immune system to be self-tolerant is the education of thymus T
cells during development. In the thymus, self-reactive cells are
either eliminated or differentiated into tolerogenic Foxp3+ Tregs
(152). Apart from the thymus, the immune system is also educated
in the gut, where it has been shown that the interaction of T cells
with commensal microbiota results in the peripheral generation of
Tregs rather than pathogenic effector cells. Failure of this tolerogenic process can lead to the development of autoimmune diseases, including colitis (152).

Microorganisms Encountered Early in Life
Prevent Autoimmunity and Allergy

The human microbiome is important for human health, behavior, and disease, yet its function and dynamics during healthy
and disease states are not fully understood (153). It is also not
fully understood how the microbiome interacts with the host immunity thereby preventing autoimmunity. The hygiene hypothesis first put forward by Strachan (154) postulates that the lack of
early exposure to microorganisms (either beneficial or pathogenic)
would lead to poor development of the immune system. The leading idea is that some microorganisms that coevolved with us are
able to protect against a large spectrum of immune-related disorders (155). Although the hygiene hypothesis is not universally
applicable, it offers some explanative power to interpret the effects of microorganism exposure in early life on preventing autoimmunity and allergy.
Children growing up on dairy farms are protected from allergy, hay fever, and asthma (156, 157). Asthma is a chronic inflammatory disease triggered by acute inflammation of the bronchial tube, leading to production of extra mucus. This can make
breathing difficult and trigger coughing, wheezing, and shortness
of breath. The number of asthma cases is increasing all over the
world, but the causes remain obscure. It has been hypothesized
that increased cleanliness, reduced family size, and subsequent
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decreased microbial exposure could explain the increases in global
asthma prevalence (158). Evidence from bronchial brushings implicates phyla present in healthy individuals with variation present in disease conditions such as cystic fibrosis, chronic obstructive airways disease, and asthma. The microbiome can exacerbate
the phenotypes seen in the condition, as well as explain the variability in phenotypes observed (159). Many cytokines and chemokines are involved in the pathophysiology of asthma. Th2 cytokines
may play an important role in the pathophysiology of asthma. The
Th1 cells secrete IL2 and IFNγ, whereas the cytokines, IL4, IL5, IL9,
and IL13 are derived from Th2 cells, although they may also be
derived from other cell types. The distinction between Th1 and
Th2 cells is not as distinct in humans as in mice (160, 161). According to the hygiene hypothesis, the lack of infection and exposure to environmental endotoxins may alter the balance between Th1 and Th2 cells.
Although children on farms are much less likely to get
asthma, the underpinnings of protection are not clearly understood. Early-life contact with livestock and their fodder and consumption of unprocessed cow’s milk have been identified as the
most effective protective exposures. Studies of the immunobiology of farm living point to activation and modulation of innate
and adaptive immune responses by intense microbial exposures
(162). Schuijs and colleagues (157) demonstrated that chronic exposure to low-dose endotoxin or farm dust protects mice from
developing house dust mite (HDM)-induced asthma. Endotoxin
reduced epithelial cell cytokines that activate dendritic cells (DC),
thus suppressing type II immunity to HDM. Loss of the ubiquitin-modifying enzyme A20 in lung epithelium abolished the protective effect. An SNP in the gene encoding A20 has been associated with allergy and asthma risk in children growing up on
farms. Thus, the farming environment protects from allergy by
modifying the communication between barrier epithelial cells
and DCs through A20 induction.
From delivery, the microbiome assembly might influence
asthma. Babies born via C-section, who experience an altered trajectory of microbiome assembly, are more prone to asthma than
those born vaginally. Similarly, children treated with antibiotics are
also more prone to asthma attack (163). Lif Holgerson and colleagues (164) analyzed the oral biofilm in healthy 3-month-old infants born by C-section or delivered vaginally. Among more than
300 bacterial taxa analyzed, Slackia exigua was detected only in infants delivered by C-section. Furthermore, significantly more bacterial taxa were detected in the infants delivered vaginally (79 species/species clusters) compared with infants delivered by C-section
(54 species/species clusters). Overall, the vaginally delivered infants had a higher number of bacterial taxa. A higher prevalence
of salivary Streptococcus salivarius, Lactobacillus curvata, Lactobacillus salivarius (L. salivarius), and Lactobacillus casei (L. casei) was
detected in infants delivered vaginally (165).
A longitudinal human study by Arrieta and colleagues (166)
reported that infants at risk of asthma have transient gut microbial dysbiosis during the first 100 days of life. The authors collected stool and urine samples from more than 300 babies at 3
months and 1 year, as well as information on their health at 1, 3,
and 5 years. Then, they analyzed levels of gut microbes in each
stool sample. Babies that had low or undetectable levels of four
bacteria, Lachnospira, Veillonella, Faecalibacterium, and Rothia, at
3 months all went on to show early signs of asthma, wheezing
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and skin allergies, at 1 year. The babies that did not develop these
symptoms invariably had high levels of the four microbes in their
3-month stool samples. The authors also used the stool samples
from the asthma-prone 3 month olds to colonize the guts of mice
that had been raised in a bacteria-free environment. The animals
developed inflamed lungs indicative of asthma. However, upon
inoculating the four missing microbes to the digestive tracts of
these mice along with the feces, they no longer had a heightened
risk of developing asthma. The studies demonstrated that certain
bacterial species that are encountered early in life could train the
immune system to prevent asthma.
Microbial dysbiosis in early life can alter the trajectory of immune development and provide the setting for allergic disorders
in later life (167). Dysbiosis may trigger autoimmune diseases via
inappropriate posttranslational modification of host proteins (168).
Endogenous and microbial enzymes have the capacity of intestinal
enzymatic neoantigen generation by posttranslational modification of host proteins. The hygiene hypothesis stipulates that microbial exposure during early life induces immunologic tolerance
via immune stimulation and hence reduces the risk of allergy development. Several common lifestyle factors and household practices, such as dishwashing methods, may increase microbial exposure. Hesselmar and colleagues (169) investigated whether lifestyle
factors are associated with allergy prevalence. The authors demonstrated that in families that used hand dishwashing, allergic diseases in children are less common than in children from families
who use machine dishwashing. The authors were of the opinion
that a less efficient dishwashing method may induce immune tolerance via increased microbial exposure.
Autoimmunity is more prevalent in the population of some
northern European countries, such as Finland and Estonia, when
compared with Russia. It was found that Bacteroides species are
less abundant in Russians but dominate in Finnish and Estonian infants. Their LPS exposures arose primarily from Bacteroides rather than from E. coli, which is a potent innate immune activator. The Bacteroides LPS was found to be structurally distinct
from E. coli LPS and inhibits innate immune signaling and endotoxin tolerance. It was observed that unlike LPS from E. coli, Bacteroides dorei LPS does not decrease incidence of autoimmune
diabetes in nonobese diabetic mice. Early colonization by immunologically silencing microbiota may thus preclude aspects
of immune education (170).
Rheumatoid arthritis (RA) is an autoimmune disease in which
the immune system attacks the joints, leading to swollen and painful joints. The mucosal surfaces are sites of rheumatoid arthritis initiation. The common occurrence of periodontal dysbiosis in
rheumatoid arthritis suggests that oral pathogens may trigger the
production of disease-specific autoantibodies and arthritis in susceptible individuals. Periodontitis is characterized by the presence
of citrullinated autoantigens that are primary immune targets in
rheumatoid arthritis. The citrullinome in periodontitis is similar to
the hypercitrullination observed in the rheumatoid joint, implicating this mucosal site in rheumatoid arthritis pathogenesis. Recent
studies identified the periodontal pathogen Aggregatibacter actinomycetemcomitans (A. actinomycetemcomitans) as a bacterial
trigger of autoimmunity in rheumatoid arthritis by inducing hypercitrullination in host neutrophils. The pore-forming toxin leukotoxin A secreted by A. actinomycetemcomitans triggers autoantigen citrullination in the rheumatoid arthritis joint (171). Zhang
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and colleagues (172) reported alterations in the gut, dental, or saliva microbiome that distinguished patients with rheumatoid arthritis from healthy controls. Individuals with rheumatoid arthritis
had low numbers of Haemophilus spp., whereas L. salivarius was
very high in these patients. It has been reported in experiments in
mice that inoculation with Bifidobacterium adolescentis (B. adolescentis) exacerbated autoimmune arthritis. B. adolescentis is known
to induce Th17 cells in the intestine (173). Interestingly, the frequencies of Th17 cells and levels of IL17 strongly correlated with
systemic disease activity at both the onset and the progression of
rheumatoid arthritis (174).

Role of Microbiome in Obesity

Obesity results from an imbalance of food intake, basal metabolism, digestive tract microbial composition, and energy expenditure (175, 176). According to Turnbaugh and colleagues (177),
the gut microbiome should be considered as a set of genetic factors that together with host genotype and lifestyle contribute to
the pathophysiology of obesity. It is observed that the intestinal
bacteria in obese humans and mice differ from those in lean individuals. Obese mice microbiota was found to be rich in Firmicutes
compared with the lean mice microbiota, which was abundant
in Bacteroidetes (177). Strikingly, colonization of germ-free mice
with microbiota from obese mice was sufficient to cause a significant increase in total body fat, as compared with colonization
with microbiota from lean mice (177). The obese microbiome has
an increased capacity to harvest energy from the diet, thereby increasing weight gain in the host (177, 178). Colonization of adult
germ-free mice with a gut microbial community harvested from
conventionally raised mice increased body fat within 10 to 14 days,
despite an associated decrease in food consumption. This change
involves several linked mechanisms: microbial fermentation of dietary polysaccharides that cannot be digested by the host; subsequent intestinal absorption of monosaccharides and SCFA; their
conversion to more complex lipids in the liver; and microbial regulation of host genes that promote deposition of the lipids in adipocytes (179).
Transfer of human microbiota to mice can phenocopy such
effects, as shown by Ridaura and colleagues (180). Cohabitation
of mice harboring an obese microbiota with mice containing the
lean microbiota prevented the development of increased body
mass and obesity-associated metabolic phenotypes in obese cage
mates. Rescue correlated with invasion of specific members of Bacteroidetes from the lean microbiota into obese microbiota and was
diet dependent. The study confirmed that specific bacteria along
with diet could induce obesity.
Childhood obesity is considered one of the most serious global
health issues in our society. Obese children are more likely to be
obese in adulthood and are at greater risk of premature death
and adverse health outcomes in later life (181). Administration of
three or more courses of antibiotics before children reach age 2
years is associated with an increased risk of early childhood obesity (182). When given early in life, antibiotics that disrupt microbiota composition, and consequently the metabolic activity of the
microbiota, can affect the body mass of the host by either promoting weight gain or stunting growth (183). The correlation of antibiotics to obesity has been earlier shown in animal models (184).
Food is broken up into components that tend beneficial microorganisms. Bacterial fermentation of a diet rich in fibers leads to
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the production of SCFA, which as noted above includes acetate,
propionate, and butyrate in the gut (185, 186). Interestingly, butyrate promotes colonic health and helps prevent cancer (185, 187,
188). The consumption of high fat and high calorie foods negatively impacts the beneficial microbes, which are believed in turn
to promote obesity. Notably, obese people have lower Bacteroidetes and more Firmicutes in their distal gut than lean subjects, and
the introduction of low fat and carbohydrate diets increased the
proportion of Bacteroidetes (175, 189).
Obesity is also known to impair cognition and produces atrophy of brain regions associated with learning and memory. In
animal studies, it has been shown that, even before the onset of
diabetes or metabolic syndrome, early-stage obesity produced
deficits on cognitive tasks that require the prefrontal cortex. Impaired cognition was associated with synapse loss, including reduced numbers of dendritic spines and expression of synaptic proteins, as well as structural alterations in the microglia. Thus, obesity
must be considered as a contributing factor to brain dysfunction
mediated through the gut–brain axis (190, 191).
It has been demonstrated recently that some bacterial species are beneficial to the host by preventing obesity. In animal
models and humans, the abundance of Akkermansia muciniphila
(A. muciniphila) is decreased in obese and type II diabetic mice
(192), and use of the bacterium as a probiotic is beneficial to the
host. Interestingly, whole bacterium is not essential to prevent
obesity. Intake of the membrane protein of the bacterium per se
could be beneficial to the host. Amuc_1100, a specific protein
isolated from the outer membrane of A. muciniphila, interacts
with TLR2, is stable at temperatures used for pasteurization, improves the gut barrier, and recapitulates the beneficial effects of
the bacterium (193).
Metformin is a well-established drug in the management of
type II diabetes and obesity. Recent studies suggest that the microorganisms are involved in mediating the beneficial effects of
metformin on glucose metabolism. Metformin shifts gut microbiota composition through the enrichment of mucin-degrading A.
muciniphila as well as several SCFA-producing microbiota, including Butyrivibrio, Bifidobacterium bifidum, Megasphaera, and Prevotella (194). Overall, there is substantial evidence of the key role
of microbiota in obesity and its adverse effects.

Microbiome and Cardiovascular Diseases

The gut microbes produce a large range of metabolites that
act not only in the gut, but also systemically, and this large pool
of known and unknown metabolites is not fully understood (195).
The metabolite trimethylamine N-oxide (TMAO) is the first potentially direct link between the gut microbiota and atherosclerotic
heart disease. Trimethylamine is produced by the gut microbiota
from nutrients containing l-carnitine, choline, and phosphatidylcholine and is subsequently oxidized by hepatic flavin-containing
monooxygenases to TMAO. TMAO has been proposed to interfere with cholesterol transportation, and TMAO precursors promote foam cell formation and atherosclerosis in animal models,
but not in the presence of antibiotics to the drinking water, suggesting a microbiota-dependent mechanism (195).
Hypertension is a risk factor for coronary heart disease, yet
whether gut microbiota dysbiosis is involved in the development
of hypertension remains largely unknown. In a recent study, it was
observed that the bacterial genus Prevotella and Klebsiella were
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overrepresented in individuals with hypertension. Fecal transplantation from hypertensive human donors to germ-free mice increased blood pressure in animals, thereby demonstrating the direct influence of gut microbiota on high blood pressure (196).
Beneficial microorganisms are known to protect against atherosclerosis. The lack of gut microbiota in germ-free apolipoprotein E (ApoE)-null mice, an experimental model of human atherosclerosis, was found to induce the development of atherosclerotic
plaques even when animals were fed a standard low-cholesterol
diet. Colonization with normal human microbiota prevented atherogenesis in germ-free ApoE-null mice fed a standard low-cholesterol diet but not a diet with high-cholesterol content (197).
The bacterial genera Eubacteria, Anaeroplasma, Roseburia, Oscillospira, and Dehalobacteria appeared to be protective against atherosclerosis and showed significant negative correlation with atherosclerotic plaque size and plasma adipocyte fatty acid binding
protein and cholesterol (198). A. muciniphila is also beneficial to
the heart. The bacteria attenuate atherosclerotic lesions by ameliorating metabolic endotoxemia-induced inflammation through
restoration of the gut barrier (199).

Microbiome and Behavior

The exponential growth in our collective knowledge of the human microbiome has seen the study of gut microorganisms move
beyond the traditional preserve of strictly microbiological disciplines. As our appreciation of the structure and dynamics of the
gut microbiome has flourished, so too has our grasp of the implications for host physiology in health and disease. Perhaps one
of the more surprising aspects of this host–microbe dialogue is
the complex interactions that manifest as alterations in brain and
behavior. Moreover, the bidirectional nature of this conversation
needs to be considered in the context that disruptions to CNS
function can be expressed distally as alterations in microbiome
composition and function in the gastrointestinal tract. These aspects of host–microbe dialogue are generally important to medicine, due to the impact of behavioral states that widely impact
and/or reflect the operation and progression of pathogenic processes and their treatment (e.g., the negative impact of depression on general therapeutic compliance).
These complex reciprocal interactions are facilitated by the microbiome–gut–brain axis, which incorporates the gut microbiome
as a critical node of the communication network encompassing
the CNS, the neuroendocrine and neuroimmune systems, the sympathetic and parasympathetic arms of the autonomic nervous system, and the enteric nervous system (200). The focus on the gut
microbiome has proved to be a surprisingly fertile ground, and
the evidence garnered from a variety of preclinical approaches has
converged to illuminate how the gut microbiome regulates multiple behaviors, physiologic readouts, and indeed many fundamental aspects of brain function.
In this regard, surveys of microbiota-deficient germ-free animals have proved particularly informative. The use of these animals in general is not new, but their application to CNS-directed
queries has been a notable feature of recent research efforts (201,
202). From a behavioral perspective, these animals display a less
anxious phenotype (203–206), and this atypical performance can
be normalized if the animals are colonized postweaning (205). Remarkably, it has also been demonstrated using both the germ-free
paradigm and an antibiotic-induced microbiota deficiency that
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anxiety-like behaviors can be transferred via the gut microbiota
by means of a fecal transplant (207, 208). Germ-free animals also
display alterations in social behaviors (209, 210) and, insofar as it
has been logistically possible to address in detail in this paradigm,
aspects of cognitive function (211). Gut microbiota depletion using a cocktail of antibiotics from early adolescence in mice replicates many of the behavioral characteristics of germ-free mice,
including reduced anxiety-like behaviors and impaired cognitive
performance (212).
Other approaches have both largely supported and extended
the behavioral picture painted by microbiota-deficient animals.
For example, administration of a probiotic L. rhamnosus strain reduced anxiety and depression-related behaviors (213), while alternative candidate probiotics, including a B. longum strain, exerted a beneficial impact on cognitive processes (214). Prebiotics
(e.g., fiber-rich foods that can influence the microbiome) can also
exert anxiolytic effects (215), while bacterial infection with an enteric pathogen can impact both learning and memory (211) and
modulate pain behaviors (216).
Physiologically, germ-free animals also exhibit profound differences with conventionally colonized controls. These differences include a defective immune system and exaggerated corticosterone
outputs to acute stressors (205, 217, 218). The microbiome is also
required for the development of microglia, cells that defend the
CNS. Microglia from germ-free mice had altered gene expression
that influenced its development (219).
An increased availability of tryptophan, the amino acid precursor to neuroactives such as serotonin and kynurenine pathway
catabolites, as generated respectively by indoleamine 2, 3-dioxygenase (IDO1) or TPH, is one feature of the germ-free state (205,
220, 221). Many aberrant physiologic features can be rescued if
the animals are colonized with a normal microbiota, especially if
this intervention takes place during specific time windows postweaning (205, 217). As is the case for behavior, other microbiota
manipulations, such as rendering mice microbiota deficient or probiotic ingestion by rodents, can also impact parameters such as
corticosterone outputs or tryptophan availability (212, 213, 222).
The reciprocal interaction between stress and the microbiome
is a particularly interesting facet of this bidirectional relationship.
As indicated above, the gut microbiota exert an influence on the
hypothalamic–pituitary adrenal axis, the main host stress response
system, and this can be captured by measuring cortisol in humans
or corticosterone in rodents (223). There are now studies showing that the opposite is also true and that a variety of stressful insults that are linked to psychopathology in adulthood can alter the
composition of the gut microbiome in animal models. This is reflected in studies that have examined early-life stress (224, 225),
prenatal stress (226, 227), and psychosocial stress (228–230). Interestingly, the gut microbiota seems necessary for the expression
of some of the pathologic behavioral features induced by maternal separation (231), a well-validated early-life stress-based model
of gut–brain axis dysfunction (232). In the clinical setting, maternal prenatal stress is also associated with alterations in the infant
gut microbiome (233). Another example of such feedback loop is
stress-related microbiome–gut–brain axis dysfunction in irritable
bowel syndrome (234).
Growing up, germ-free influence biological function such as
blood–brain barrier integrity (235), transcriptional regulation (203,
236), neurogenesis (237) microglial function (238), and myelination
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(239). Recently, it has been demonstrated that a germ-free mouse
model of Alzheimer disease displayed a marked reduction of cerebral amyloid pathology and that colonization of these mice with
the gut microbiota of their conventionally colonized counterparts
reinstated the amyloid pathology (240). Although the behavioral
implications of these altered amyloid phenotypes requires elaboration, this intriguing study does provide support for the hypothesized role of the gut microbiota in neurodegenerative disorders (241).
The mechanisms underpinning influence of the gut microbiome
on brain and behavior are under investigation. The gut microbiota
is required for motor deficits, microglia activation, and α-synuclein
pathology. Colonization of microbiota from Parkinson disease–
affected patients enhances physical impairments compared with
microbiota transplants from healthy human donors. Thus, the gut
bacteria are involved in movement disorders, and alterations in
the human microbiome represent a risk factor for Parkinson disease (242). Recently, the role of the vagus nerve (the main neural
communication highway between the gut and the brain) has attracted much attention (243). It has been demonstrated, for example, that the beneficial CNS impact of a probiotic was abolished
in vagotomized mice (213), while the anxiety-like behaviors that
emerge in a colitis model were absent in previously vagotomized
mice (207). The vagus nerve is not the sole conduit linking the gut
and the brain (244), and a variety of alternatives have been considered. These include microbial regulation of tryptophan metabolism (245), microbial metabolites, such as SCFAs (246) or indoles
derived from tryptophan (247), neuropeptide production (248) as
well as immunomodulation (249). The important role of the gut
microbiota in maintaining intestinal barrier integrity also needs to
be taken into account (250, 251).
The landscape for manipulating the microbiome is broad and
increasingly financed (252). Considerations are being given to
priming interventions that promote assembly of the infant microbiome (65, 253, 254), sustain the gut microbiota in healthy
aging (125, 126), more radical options such as fecal microbiota
transplantation (255) as well as less controversial options such
as psychobiotics (256), exercise (257, 258), and diet-based manipulations (259, 260). Indeed, a number of small studies using
healthy volunteers have now demonstrated that ingestion of certain cocktails of probiotics, a fermented milk product with probiotic or prebiotics, can impact on the CNS (261–264). Autism
spectrum disorders are complex neurobiological disorders characterized by impairment in social interaction and communication
and restricted, repetitive, and stereotyped patterns of behavior,
interests, and activities. Autistic children suffer from gastrointestinal disorders. Autistic children have less diverse microbial
population in the gut and significantly lower abundances of the
genera Prevotella, Coprococcus, and Veillonellaceae involved in
carbohydrate metabolism (265).
Future directions will likely see further elaboration of the role
of the gut microbiome in sleep (266) and circadian rhythms (267–
269). Our awareness of the interface between natural and built
environments, the gut microbiota, and human behavior is also
growing (270–272). Of course, a key caveat is to what degree this
promising but largely preclinical body of research will effectively
impact the clinical setting. Moving from mouse to man, be it in the
context of CNS-directed or gastrointestinal-focused research, is of
course complicated for stress-related neuropsychiatric and other
heterogeneous disorders associated with the gut microbiome (273,
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274). Of equal importance is the necessity to address the issue
of whether the correlations that have been noted thus far between multiple disorders and the gut microbiota alterations are
in fact causal relationships. Such obstacles are not insurmountable
with due diligence and the necessary multidisciplinary expertise
required to exploit the considerable opportunities presented by
host–microbe interactions.

Beneficial Microorganisms Restrict the
Outgrowth of Pathogens in the Gut
The human microbiota encompasses all the microorganisms
that reside on the skin and in all other tissues and organs, including the gastrointestinal tracts. Of these body sites, the gastrointestinal tract is the most densely colonized organ. The microbiome includes bacteria, fungi, and archaea (275). There are approximately
1,000 species of microbes colonizing the gut, with densities of 104
to 105 bacteria per millimeter of digestive effluent in the proximal
small intestine and 1011 bacteria per gram of luminal content in
the colon (276). The physicochemical conditions in the gut influence the composition of the intestinal microbiota (277). The gastrointestinal tract harbors many distinct niches, each containing a
different microbial ecosystem that varies according to the location
within the gastrointestinal tract. The microbial density increases
along the gastrointestinal tract with 101 to 104 microbial cells in the
stomach and duodenum, 104 to 108 cells in the jejunum and ileum,
to 1010 to 1012 cells per gram in the colon and feces (277–279).
The majority of all microorganisms in the human digestive
tract are bacteria and belong to two phyla, the Bacteroidetes and
the Firmicutes (280). In addition, the other significant phyla occupying the digestive tract include Proteobacteria, Actinobacteria,
Fusobacteria, Spirochaetes, Verrucomicrobia, and Lentisphaerae
(281, 282). The methanogens Methanobrevibacter and Methanosphaera are the most dominant archaeal groups (7, 283). The
two common fungal phyla in the gut include Ascomycota (which
includes the genera Candida and Saccharomyces) and Basidiomycota (30, 284).
Intestinal microbiota play a central role in the metabolic, nutritional, physiologic, and immunological processes of the human
body, processing indigestible dietary polysaccharides, including
resistant starch and dietary fibers, thereby leading to the production of important nutrients, such as SCFAs, vitamins (vitamin K, vitamin B12, folic acid), and certain amino acids that humans are
unable to synthesize themselves (279, 285, 286). The plant polysaccharides in our diet are rich in xylan-, pectin-, and arabinose-containing carbohydrate structures. The human genome lacks most
of the enzymes required for degrading these glycans. Nevertheless, the distal gut microbiome provides us with this capacity to
process these polysaccharides. The human gut microbiome is enriched for genes involved in glucose, galactose, fructose, arabinose, mannose, and xylose, starch, and sucrose metabolism. Our
microbiome also has significantly enriched metabolism of glycans,
amino acids, and xenobiotics, methanogenesis, and 2-methyl-Derythritol 4-phosphate pathway–mediated biosynthesis of vitamins
and isoprenoids (7). The intestinal microbiota also participates in
the defense against pathogens by mechanisms such as colonization resistance and production of antimicrobial compounds. Furthermore, the intestinal microbiota is involved in the development,
maturation, and maintenance of the gastrointestinal sensory and
motoric functions, the intestinal barrier, and the mucosal immune
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system (279). The microbiota of the intestine is also involved in
promoting bone formation as well as resorption, leading to skeletal growth. Microbiota induces the hormone insulin-like growth
factor 1 (IGF-1), promoting bone growth and remodeling. When
the microbiota ferment fiber, SCFAs are produced, leading to induction of IGF-1 that promote bone growth (287).
The very high microbial content of the large intestine poses
a major challenge to the mucosal immune system, as it needs
to tolerate commensal microbiota and dietary antigens while
maintaining the ability to eliminate pathogens. Induction of colonic Treg is crucial in fostering this immune homeostasis (288).
CD4+CD25+FOXP3+ Tregs are of two types: thymus-derived Tregs
(tTreg) and peripherally derived Tregs (pTreg). Although it is difficult to distinguish these types phenotypically, both are thought to
have an essential role in immune regulation (288). Although tTregs
develop in the thymus, the major site for pTreg development is the
colon, resulting in a large population of regulatory cells that have
a distinct T-cell receptor (TCR) repertoire and are critical for intestinal homeostasis (152). Notably, the development of pTregs requires microbiota to be present in the colon. Although the mechanism of induction of colonic pTregs is not understood, several
microbial components have been found to enhance their expansion and function, including SCFAs and polysaccharide A of Bacteroides fragilis (B. fragilis; ref. 288). Acetate, propionate, and butyrate are the three main SCFAs, and butyrate has been found to
be the most potent inducer of colonic Tregs.
The newborn infant is colonized at birth with microbes from the
mother’s vaginal and fecal microbiota as well as with other environmental microbes encountered in the first days of life (289). The
mode of delivery influences the microbial composition in man. An
article by Penders and colleagues (93) demonstrated that the important determinants of the gut microbiome composition in infants were the mode of delivery, type of infant feeding, gestational
age, infant hospitalization and antibiotic use in the infant. Term infants born vaginally and exclusively breastfed had the most “beneficial” gut microbiota (had the highest numbers of Bifidobacteria
and lowest numbers of C. difficile and E. coli). In contrast, infants
born through C-section had lower numbers of Bifidobacteria and
Bacteroides, and they were more often colonized with C. difficile,
as compared with vaginally born infants. Exclusively formula-fed
infants were more often colonized with E. coli, C. difficile, Bacteroides, and Lactobacilli, as compared with breastfed infants. Hospitalization and prematurity were associated with higher prevalence
and counts of C. difficile. Administration of antibiotics to infants
was associated with decreased numbers of Bifidobacteria and Bacteroides. Infants with older siblings had slightly higher numbers of
Bifidobacteria, compared with infants without siblings (93, 290).
C. difficile is an opportunistic, anaerobic Gram-positive, sporeforming, toxin-producing bacillus that is transmitted among humans through the fecal–oral route. Notably, the pathogen is generally present in the human gut, but it does not cause any disease
under normal conditions. Abuse/misuse of antibiotics destroys
beneficial microbiota that enables the proliferation of C. difficile,
leading to pathogenic conditions. Ampicillin, amoxicillin, cephalosporins, clindamycin, and fluoroquinolones are the antibiotics
most frequently associated with disease, but almost all antibiotics have been associated with increased rates of opportunistic infection. C. difficile colonizes the large intestine and releases the
exotoxins TcdA and TcdB that cause colitis in susceptible persons
(291, 292). C. difficile has emerged as a major enteric pathogen
with worldwide distribution. In the United States, C. difficile is
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the most frequently reported nosocomial (i.e., hospital-acquired)
pathogen. A recent surveillance study identified 453,000 cases of
C. difficile infection and 29,000 deaths associated with C. difficile
infection; approximately, a quarter of those infections were community acquired (293). The antibiotics prescribed to control C.
difficile include metronidazole, vancomycin, fidaxomicin, or surgery in extreme cases of infection (294). Fecal transplant is emerging as an alternative strategy for treating recurrent C. difficile infections (295). Use of probiotics (such as beneficial bacteria and
yeast), which help restore a healthy balance to the intestinal tract,
is safe and effective for preventing C. difficile–associated diarrhea
(296). Thus, beneficial microorganisms are essential to maintain
the human gut immune homeostasis, thereby preventing pathogenic infections. Further contributing to such defenses, beneficial microorganisms also modulate epithelial cell proliferation, villus architecture, and angiogenesis within the intestine, along with
xenobiotic metabolism, bone mineral density, behavior, and key
metabolic functions (297, 298). Tipping the balance favoring the
expansion of enterobacteria is one of the causes of several inflammatory bowel diseases. However, it is not known how the favorable
bacteria prevent dysbiosis. A recent study demonstrated that microcins, the small proteins secreted by several favorable bacteria
could limit the expansion of competing Enterobacteriaceae (299).

Microbiome Effects on Intestinal Barrier
Function and Inflammatory Bowel Disease
Mammals, including humans, support one of the most complex
microbial ecosystems. Although the immune system is classically
thought to have evolved to provide protection from infection by
microbial pathogens, animals peacefully coexist with a vast and
complex microbiota, which extensively interacts with the immune
system. It has recently been proposed that the total information
encoded by the mammalian genome is not sufficient to carry out
all functions that are required to maintain health and that products
of our microbiome are crucial for protection from various diseases
(300). It is possible that alterations in the development or composition of the microbiota (dysbiosis) disturb the partnership between the microbiota and the human immune system, ultimately
leading to altered immune responses that may underlie various
human inflammatory disorders (146).
In inflammatory bowel disease (IBD), the role and interplay of
the microbiome (301–303) with a gastrointestinal barrier compromise (304–306) has been the subject of extensive review (307–
311). Gastrointestinal barrier function is not governed solely by
the tight junctional complex, although this focus has certainly
attracted the greatest basic research interest. Tight junctions
form the continuous intercellular barrier around epithelial cells,
which are required to separate tissue spaces and regulate selective movement of solutes across the epithelium (312). From a
wider perspective, gastrointestinal barrier function also may be
compromised by an impaired mucus layer over the epithelium
[a topic reviewed nicely by others recently (Chen and colleagues;
ref. 313)], as well as by cell death in the epithelium or an epithelial–mesenchymal transition leading to impaired cell adhesion/
attachment (to other cells and substratum). Leak at the sites of
compromised tight junctions may be quite distinct in nature from
the leak at the sites of cell death (314). Likewise, the remediation
of leak is very different in these cases; repair of leak from impaired tight junctions may be a purely transcription/ translation/
phosphorylation–based process, whereas remediation of leak due
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to cell death/dedifferentiation/detachment could also require a
careful orchestration of cell motility and cell replication. In these
different cases, the microbiome may exert control over very different processes. It is worth considering that any given specific
case of IBD likely involves gastrointestinal leak from all of these
causes, and therefore alleviation of such leak, and the inflammatory cascades it gives rise to, is a quite complex task. Further
research is required to determine whether microbiome may be
better at repair of one type of leak than the other.
There is no doubt that IBD is in part driven by a breakdown or
compromise of the gastrointestinal epithelial barrier, and many
reviews on IBD have dealt with this feature as mentioned above.
There is some controversy concerning whether a compromise of
barrier function is the initial causation of the disease. The findings that asymptomatic, first-degree relatives of IBD patients in
fact harbor molecular-level leak in their gastrointestinal tract mucosa have traditionally been powerful evidence tilting the argument toward causality (315, 316). The question of course that
leaps to the fore then is what induces the leak in the first place?
The very fact that a genetic element exists in IBD (e.g., in firstdegree relatives) indicates a role for genetics in the disease, but
equally obvious is that genetics is probably a necessary but insufficient condition.
Studies focusing on this involvement of gastrointestinal microbiome in IBD take two forms: (i) whether the microbiome is abnormal in IBD and possibly playing a role in etiology; (ii) whether a
microbiome modification can be designed as a therapeutic option
in the disease. The second possibility appears achievable: Some
of the best clinical evidence, on the basis of its very applicability,
is the success of “fecal transplant” procedures in achieving therapeutic efficacy in IBD (317, 318). Prior to the recent advent of these
protocols, there was the use of butyrate enemas to achieve therapeutic relief (286, 319, 320). The therapeutic efficacy of luminal
administration of butyrate is cogent testimony to the positive role
played by the normal microbiome in maintaining a functional epithelial barrier in the gastrointestinal tract, as well as to the utility
of targeting the microbiome as a viable clinical approach to IBD.
Butyrate is a significant metabolite of dietary fiber by the normal
gastrointestinal microbiota (321), with butyrate levels in the gastrointestinal lumen being the highest in the body. Butyrate has
been found in many recent in vitro studies to be highly effective
in inducing structural changes to the epithelial tight junction complex, resulting in improved epithelial barrier function (322, 323).
A similar literature also exists for the gastrointestinal microbiota
metabolite, indole, a product of tryptophan metabolism by commensal bacteria (324, 325). In combination, the fecal transplant
and butyrate enema clinical studies, along with the in vitro studies of tight junction modification and enhancement by butyrate
and indole, provide a very powerful argument of not only maintenance and modification of the gastrointestinal barrier by the microbiota, but also for targeting the microbiota as a viable, effective therapeutic strategy.
Better delineated proof of the ability of the microbiota to both
positively and negatively affect the gastrointestinal barrier comes
out of animal model and epithelial cell culture studies. For example, the probiotic bacterium, L. casei, both strengthened barrier function and decreased proinflammatory cytokine content in
BALB/c mice (326). In addition, such treatment also modified the
gastrointestinal microbiota overall. The probiotic and commensal bacteria L. rhamnosus and F. prausnitzii have also improved
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barrier function, as demonstrated in studies with CACO-2 cell culture models and experimentally induced colitis in C57BL/6 mice
(327, 328). The microbiome is also known to be involved in the
wound healing of the mucosa of the gut (329). In mice, it has
been demonstrated that mucosal injury leads to increase in the
expression of formyl peptide receptor 1 (FPR1) and neutrophilic
NADPH oxidase (NOX2) that causes depletion of oxygen resulting
in the enrichment of anaerobic bacteria. The anaerobic, mucinophilic gut symbiont, A. muciniphila, stimulated proliferation and
migration of enterocytes adjacent to the colonic wounds mediated through FPR1 and intestinal epithelial cell–specific, NOX1dependent redox signaling, thereby leading to wound healing
of the mucosa. These findings highlight a very important consideration in studies of the microbiota, barrier function, and IBD,
namely that not only can microbiota affect barrier function, but
modification of barrier function (good and bad) may well affect
microbiota composition, a “research road less traveled.” This less
investigated area is well illustrated by the finding that anti-TNF
immunologic medications, which reduce proinflammatory cytokines and allow for barrier repair, also result in changes in microbiota composition (330).
It is worth noting too that a factor as omnipresent as diet can
affect both barrier function and microbiota while also simultaneously affecting cytokine production. Administering a high-fat
“Western” diet to CEABAC10 mice induced deleterious changes
in gastrointestinal microbiota (e.g., increased content of adherent-invasive E. coli), decreased mucus layer protection, and led to
gastrointestinal barrier compromise (331). Pathogenic E. coli have
been implicated in Crohn disease, in part due to an ability to not
produce cell death while inducing synthesis of copious amounts
of TNF (332). The dietary connection to an altered microbiota in
terms of pathogenic bacteria is also apparent in the finding that vitamin D deficiency enables the barrier-disruptive effects of pathogenic E. coli to be manifested (333). Even more fascinating and less
intuitive is an effect of the environment at large on barrier function, microbiota, and inflammatory status, as Kish and colleagues
(334) show for particulate air pollutants. It will be instructive to discover in future research whether the principal actions of diet/nutrition/ environment are on microbiota directly and barrier function indirectly, or vice versa.
As more and more studies reveal the intricate interplay between gastrointestinal barrier function, gastrointestinal microbiota, and degree of inflammation, it is worth considering that the
effects of microbiota on barrier function, and barrier function on
microbiota, will in large degree derive from actions of protein kinases in signaling pathway transduction systems. This has been recently very well reviewed by Yang and Yan (335). One would caution however against taking an aggressively reductionist approach
in dealing with the interplay of microbiota, barrier function, and
inflammation: The complexity of the gut microbiome in the gastrointestinal tract, the complexity of the signaling pathways known
to regulate barrier function, and the complexity of cytokine interactions all suggest strongly that one needs to tread carefully in
what may well be overly ambitious undertakings to find and utilize specific molecular mechanisms involved in this intricate relationship. A properly functioning gastrointestinal mucosa is in essence a symphony scored by microbiota “strings,” barrier function
“woodwinds,” and immune regulatory “brass.” To search for an allpivotal kinase or phosphatase responsible for gastrointestinal mucosal homeostasis may be analogous to trying to claim a single
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flute or viola as the fulcrum of Beethoven’s Ninth, a fool’s errand
that ignores the extreme complexity and subtlety of the gastrointestinal environment.
Because of the still singular importance of the studies showing
epithelial barrier compromise in asymptomatic first-degree relatives of IBD patients to the field of IBD research, it will be very interesting to observe the outcome of studies yet to be performed
on the microbiome of first-degree relatives of IBD patients. It is
likely that those results could be just as pivotal to the future understanding of IBD as were the now-long-ago studies of May and
Hollander on barrier function and IBD (315, 316).
Increased risk of developing IBD may be due to improved hygiene practices. Ramanan and colleagues (336) showed that intestinal helminth infection, caused by parasitic worms, protects
IBD-susceptible mice from developing the disease. The infection
of parasitic worms increased specific protective species and limited other inflammatory members of the microbiota. People from
helminth-endemic regions harbored a similar protective microbiota, and their deworming led to an increase in inflammatory Bacteroidales, as observed in the mice. Thus, a changing microbial
environment may shape susceptibility to inflammatory disease.
Although we currently know at least a partial membership of
the human microbiome, we are yet to fully understand how these
microorganisms are contained in the intestine. Anatomy of the
colon by light microscope reveals a mucus layer, mucosa, submucosa, gut-associated lymphoid follicle, and muscularis. The intestinal/colonic mucus is an efficient system for protecting the epithelium from bacteria by promoting their clearance and separating
them from the epithelial cells, thereby inhibiting inflammation and
infection (337). Colonic mucus is produced by the goblet cell. The
main mucus component in the intestine is MUC2 mucin, a large
and heavily O-glycosylated gel-forming mucin that forms enormous polymeric nets by C-terminal dimerization and N-terminal
trimerization. Upon secretion from the goblet cells, the mucus expands rapidly and builds a stratified dense layer that is attached to
the epithelium. Normal human sigmoid colon has an inner mucus
layer that is impenetrable to bacteria. At a distance far from the
epithelial surface, the inner mucus is transformed into a soluble
and less organized outer mucus layer that by proteolytic expansion
generates the preferred habitat for the commensal microbes (338).
IBDs are characterized by aberrant innate and adaptive immune
responses to commensal luminal bacteria (339). Ulcerative colitis
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is thought to be caused by some strains of E. coli (340). In cell culture models, it has been shown that ulcerative colitis-associated
E. coli producing α-hemolysin can cause rapid loss of tight junction integrity (341). The human intestinal epithelium is formed by
a single layer of epithelial cells that separates the intestinal lumen
from the underlying lamina propria and the space between these
cells is sealed by the tight junction, which regulates the permeability of the intestinal barrier (342). Tight junction complexes allow passive absorption of small hydrophilic molecules (nutrients
and ions), but they restrict passage of large molecules and infectious microbes. Ulcerative colitis is characterized by a leaky intestinal barrier due in part to defective tight junction. Our group
had reported that attenuation of the Bin1 gene in a mouse model
would protect against experimental colitis (343). On the basis of
the study, we recently demonstrated that treatment of experimental colitis with Bin1 mAb would support mucosal barrier function
by inducing the expression of tight junction proteins, thereby protecting the integrity of the lymphoid follicle. The therapy may be a
novel strategy to treat ulcerative colitis and possibly limit risks of
colorectal cancer (344). Thus, lowering Bin1 levels may be a strategy that would lead to enhanced tight junction proteins that, in
turn, protects against pathogenic microorganisms crossing the
epithelial cells.
Other strategies may be used by the epithelial cells to protect
against pathogenic microbes from entering the tissues. Recently,
while working on subconfluent CACO-2 cells (derived from the
intestine), we observed that EEA1 endosomes (early endosome
marker) were confined more toward the periphery of CACO-2 cell
monolayers. To confirm whether these endosomes are present
in the colon tissues, we stained for EEA1 in mouse colonic tissues. We observed EEA1 endosomes in the peripheral mucosa
as well as in the muscularis. Insofar, as endosomes are traditionally thought to protect against foreign bodies, including microorganisms, one might speculate that early endosomes help protect
against bacteria crossing the mucus. Microbes that overcome this
barrier to cross the mucus layer might be destroyed within endosomes, with further protection afforded by the endosomes lining
the muscularis (Fig. 1).
Additional endosomal strategies may be used to protect colonic tissues against the entry of pathogenic microbes. Endosomes
are traditionally thought to protect colonic epithelial cell layers
against microorganisms, possibly helping eliminate bacteria that

Figure 1. Early endosomes localize mainly to the periphery of colon mucosa and muscularis. A, Peripheral localization of EEA1 in a colony of human
colonic Caco-2 cells. Cells were stained with the early endosomal marker EEA1 (green) and DAPI to visualize cell nuclei (blue) and processed for immunofluorescence microscopy. B, Peripheral localization of EEA1 in murine colon mucosa processed as above. C, Peripheral localization of EEA1 in
murine colon muscularis processed as above.

14
cross the mucus layer, a strategy that also may be extended into
the subordinate muscularis layer (Fig. 1). In subconfluent human
colonic cells, which form island-like colonies in monolayer culture,
the early endosome marker EEA1 can be seen to preferentially localize to the colony periphery. Similarly, in colon tissues, early endosomes display the same localization with EEA1 staining in the
periphery of the mucosa and muscularis. Beclin1-dependent autophagy associated with the endosome pathway also has been
implicated in the bacterial and viral pathogen elimination (345),
which downregulates Beclin1 to promote virulence and infection.
Beclin1 associates with endosomes and regulates EEA1/early endosome localization and late endosome formation (346). Upon
TLR signaling, Beclin1 rapidly translocates to the phagosome and
mediates efficient phagosome–lysosome fusion to ensure rapid
acidification and efficient destruction of the pathogen (345). In
human colonic cells, Beclin1 staining occurs throughout the colon
tissue at endosomes (Fig. 2), possibly helping direct pathogenic
cargo to lysosomes and thereby restricting microbiome ecology
to the gut lumen.

IDO1 and the Microbiome–Host Interaction
As noted above, establishing and maintaining the symbiotic
mutualism that exists between the microbiome and its mammalian host necessitates the engagement of mechanisms of acquired
immune tolerance, as these microorganisms represent the epitome of non-self. IDO1 is a metabolic enzyme that has gained recognition as an important mediator of acquired immune tolerance.
IDO1 catalyzes the rate-limiting first step in the degradation of the
essential amino acid tryptophan, but is not involved in maintaining tryptophan homeostasis, which instead is the role of the distinct liver enzyme TDO2 (tryptophan dioxygenase; ref. 347). The
concept of IDO1 as an immune regulator emerged from findings
that tryptophan catabolism could suppress cytotoxic T-cell activation (348, 349). The demonstration that the IDO pathway inhibitor 1-methyl-tryptophan (1MT) could elicit T-cell– dependent rejection of allogeneic mouse concepti (350, 351) established the
physiologic relevance of tryptophan catabolism as a mediator of
acquired immune tolerance. Subsequent findings linking attenuation of the tumor suppressor gene Bin1 to IDO1 dysregulation
and tumoral immune escape (352) provided experimental substantiation for the corollary proposition that tumor cells might, by
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inducing IDO1, appropriate this mechanism of protection for the
“foreign” fetus to overcome immunosurveillance. Within the complex inflammatory milieu of the tumor microenvironment, IDO1
induction is not necessarily restricted to tumor cells, and nonmalignant stromal cells expressing IDO1 can promote tumoral immune escape as well (353). In particular, IDO1 induction in antigen-presenting cells (APC), such as DCs and macrophages, has
been implicated in promoting immune tolerance by suppressing
effector cytotoxic T lymphocytes, converting naïve T lymphocytes
to FoxP3+ Treg cells and elevating the suppressive activity of “natural” Tregs (354).
A great deal of attention is now focused on the therapeutic potential of small-molecule inhibitors of IDO1 for treating cancer patients (355), particularly in combination with cancer chemotherapy
or “immune checkpoint” antibodies (352, 356). It is not yet clear
how IDO1 may influence host interactions with the microbiome,
but there has been much attention to the related topic of its role
in the host response to infection by various pathogens, which has
been a topic of interest for a number of years. Indeed, well prior
to findings of its involvement in immune modulation, it was noted
that intraperitoneal administration of bacterial LPS could induce
IDO1 activity in the lungs of mice by 30- to 50-fold (357). This initial indication that IDO1 induction might be associated with the
inflammatory response to microbial infection was followed by reports of pulmonary IDO1 induction in response to virus infection
(358) and IFNγ (359).
As IFNγ plays a major role in controlling a variety of infections,
the finding that IDO1 is highly responsive to IFNγ spurred investigations addressing whether IDO1 might have a downstream
antimicrobial effector role. In 1984, Pfefferkorn and colleagues
reported that tryptophan degradation was responsible for the
IFNγ-mediated restriction of the growth of the obligate intracellular protozoan Toxoplasma gondii (T. gondii) in human fibroblasts
(359). IFNγ-mediated restriction of the growth of the obligate, intracellular, Gram-negative bacterium Chlamydophila psittaci was
likewise linked to tryptophan deprivation (360). These studies focused attention on IFNγ-elicited tryptophan deprivation resulting from the induction of IDO1 as mediating the antiproliferative effect on these intracellular pathogens. This assessment, that
IDO1 provides a beneficial effect in combating infections, was
complicated by additional studies demonstrating the activation
of genes for Chlamydia persistence triggered by IDO1-mediated

Figure 2. Late endosomes locate throughout colon mucosa and muscularis. A, Punctate cytosolic localization in a colony of human colonic Caco-2
cells. Cells were stained with Beclin1, an autophagic regulator associated with late endosomes (green), and DAPI to visualize cell nuclei (blue) and
processed for immunofluorescence microscopy. B, Cytosolic localization of Beclin1 in murine colon mucosa processed as above. C, Cytosolic localization of Beclin1 in murine colon muscularis processed as above.
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tryptophan depletion. Because the bacterium is sensitive to the
antibiotic treatment only when it is metabolically active, IDO1 activity in this context was detrimental to clearing infections, leading to the suggestion that tryptophan supplementation might help
overcome antibiotic resistance (361). Furthermore, although the
effects of IDO1 on microorganisms were initially attributed to depletion of tryptophan, evidence of microbial effects produced by
downstream tryptophan metabolites, from what is collectively referred to as the kynurenine pathway, were also reported (362, 363).
In particular, 3-hydroxykynurenine was shown to suppress the proliferation of S. aureus in vascular allografts (364), and both 3-hydroxykynurenine and 3-hydroxyanthranilic acid were found to contribute to controlling the replication of Trypanosoma cruzi in mice
(365). In a single report, treatment with 1MT produced three different outcomes depending on the nature of the infection, exacerbating T. gondii toxoplasmosis, restraining L. major leishmaniasis, and having no apparent effect on HSV-1 replication or latency
(366). In aggregate, the implication from these studies of infectious pathogens is that the overall impact of IDO1 activity, both in
terms of tryptophan depletion and the production of various metabolites, on the diverse ecology of the commensal microbiome
is likely to be complex and contextual.
Perhaps even more consequential than the direct effects of
IDO1 activity on particular microbes are the effects that IDO1 can
exert on the overall inflammatory environment. In accord with its
ability to elicit T-cell suppression, the general assumption has been
that IDO1 should act in an immunosuppressive manner to limit the
severity of inflammation. Data supporting this interpretation have
been reported in a mouse model of chronic granulomatous disease in which defective IDO1 function in mice lacking an essential
component of NADPH oxidase, p47phox, was implicated in the exaggerated inflammatory response to infection with Aspergillus fumigatus (367). The more severe illness was associated with higher
numbers of IL17-producing γδT cells and fewer IL10-producing
αβTregs, which could be reversed by the provision of exogenous
kynurenine. However, as with the effects of tryptophan catabolism on microorganisms, the categorization of IDO1 as strictly immunosuppressive may be an oversimplification (368). In a mouse
model of chemical carcinogenesis, genetic loss of IDO1 did not exacerbate inflammation in response to phorbol ester–elicited tumor
promotion, as would be expected if it were broadly immunosuppressive, but did result in a dramatically reduced incidence of premalignant lesions (369). Perhaps even more strikingly, in a mouse
model of rheumatoid arthritis, 1MT treatment suppressed rather
than exacerbated joint inflammation (370), whereas in a contact
hypersensitivity model, genetic loss of IDO1 resulted in diminished
ear swelling (371). Why IDO1 has such varied effects on the inflammatory response remains to be fully elucidated, but suggests
that the outcome of the interactions with the complex microbiome may be contextual and difficult to predict.
The study in the rheumatoid arthritis model noted above also
highlights a particular complication with interpreting results of the
many studies that have relied on the use of the compound 1MT to
inhibit IDO1 activity. Biochemical and pharmacologic evaluation
of this compound clearly indicates that it is not directly inhibiting
the enzyme at the dose ranges administered in vivo, and it is able
to signal as a mimetic for tryptophan sufficiency and thereby interfere with activation of downstream response pathways (372).
However, a tryptophan deficiency signal can be provided by any
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of the enzymes that catalyze tryptophan degradation (IDO1, IDO2,
TDO2, as well as TPH, the latter of which initiates an alternate pathway of tryptophan catabolism to serotonin). Therefore, 1MT is not
a valid tool to discriminate which of these particular enzymes is involved. Indeed, in the rheumatoid arthritis model, genetic analysis
revealed that the recently identified paralog IDO2, and not IDO1,
is likely to be responsible for the effect of 1MT on joint inflammation, as the effect of 1MT administration was phenocopied in mice
lacking IDO2 but not IDO1 (370, 373). Studies using later generation, direct enzyme inhibitors (355), coupled with studies in genetically modified animals (371, 374, 375) can overcome ambiguities in data interpretation associated with 1MT treatment. Indeed,
a recent study of LPS responses utilizing the IDO1, IDO2, and Tdo2
gene deletion mouse strains provides confirmatory evidence that
these three genes have distinct, nonoverlapping roles in the host
immune response to this microbial signal (376).
Although the regional microbiome present at all barrier surfaces is likely to influence immunity locally, the microbiome of
the gastrointestinal tract is of particular interest because of the
broader role it has been found to play in shaping systemic immune homeostasis (377). Correspondingly, current microbiome
research is largely focused on the gastrointestinal tract, where
commensal microorganisms have been found to contribute to
host defense by limiting the growth of enteric pathogens and
producing symbiosis factors that control intestinal inflammation and pathology (377). Evidence implicating IDO1 in this process has come from a study of the protective capacity of L. salivarius, which is abolished in mice lacking the gene encoding
NOD2, an intracellular pattern recognition molecule that regulates inflammatory pathways in response to detection of bacterial peptidoglycans. In this model, IDO1 upregulation was found
to correlate with NOD2-dependent protection (378). The increased regulatory complexity imposed by the gut microbiome
may help also explain counterintuitive findings associated with
IDO1 in this tissue. In a dextran sodium sulfate/1,2-dimethylhydrazine–elicited model of colon carcinogenesis, genetic loss of
IDO1 resulted in increased tumor frequency (379), unlike other
organ systems in which IDO1 loss has been associated with resistance to carcinoma development (380, 381). This outcome is
similar to the atypical impact on tumor formation ascribed to
Tregs in the gut, where their presence appears to be protective against carcinogenesis (382), despite evidence that Tregs are
generally associated in other organs with tumor promotion. It
has been proposed that the effect of immunosuppressive mechanisms on inflammatory pathology of the gut may be quite different depending on whether there is any initial involvement of
tissue damage, as the resulting microbial translocation produces
a severe tumor-promoting inflammation (383). Under these circumstances, dampening the inflammatory response via immunosuppressive mechanisms may provide a more consequential
benefit that overshadows any detrimental role in promoting immune escape. This interpretation is consistent with the findings
of two otherwise apparently contradictory studies in colitis models, where IDO1 blockade resulted in augmented colitis induced
by trinitrobenzene sulfonic acid (384), but diminished colitis induced by Citrobacter rodentium (385).
In conjunction with the complex immunoregulatory effects
attributed to IDO1 activity in the gut, tryptophan metabolites
produced by the microbiota affect mucosal reactivity. When

16
switching from sugar to tryptophan as an energy source, the
highly adaptive Lactobacilli in the gut expand and produce an
aryl hydrocarbon receptor (AhR) ligand, indole-3-aldehyde, that
contributes to AhR-dependent IL22 transcription. The resulting IL22- dependent mucosal response promotes the survival of
mixed microbial communities, while providing colonization resistance to the fungus Candida albicans and mucosal protection
from inflammation. This example of coevolutionary commensalism through the microbiota–AhR axis represents yet another way
in which tryptophan catabolism appears to be involved in fine
tuning host mucosal reactivity (386). As further investigations
into the physiologic and pathophysiologic interactions between
IDO1, the commensal microbiome and host immunity are conducted, the indications from these early studies are that IDO1 is
likely to play an integral but contextual role at the interface between homeostasis and dysbiosis.

Microbiome and Cancer
The interplay between microbes, cancer, and the immune system is in no manner fully defined. However, accumulating evidence
argues provocatively that microbes exert a variety of functions on
host oncogenesis, tumor progression, and response to immunotherapy. Thus, selectively manipulating the gut microbiome is a
critical parameter to consider in the ongoing battle against established cancers.
The metabolic potential of the gut microbiota is now regarded
as vital to the process of malignant transformation. Disruption of
the intimate relationship between the host and intestinal bacteria, known as dysbiosis, can affect oncogenesis, tumor progression, and response to cancer therapy. Dysbiosis can occur for several reasons: (i) direct occupancy of unwanted, foreign microbes
(as discussed above) that outcompete friendly gut flora; (ii) a response to immunosenescence with aging; and (iii) direct environmental insults such as antibiotics and smoking (387). In the setting of chronic autoimmune processes, such as Crohn’s disease
and ulcerative colitis, the integrity of gut epithelial, myeloid, and
lymphoid components is disrupted (Fig. 3). These chronic insults
ultimately increase host’s risk for neoplastic transformation (388).
Indeed, several factors that favor carcinogenesis similarly recapitulate dysbiosis.
One well-studied model of the dysbiosis/cancer connection is
that of repeated intra-abdominal infections, the use of antibiotics, or both leading to an increased incidence of colorectal cancer
(389). In several preclinical studies, interventions that abrogate or
directly alter gut microbiome composition increase the incidence
and progression of colorectal carcinoma in both genetic and carcinogen-induced models of tumorigenesis (390–392). Moreover,
several byproducts of the gut microbiota directly target intestinal
epithelial cells and either facilitate oncogenesis (as reported for
hydrogen sulfide and the B. fragilis toxin) or suppress tumorigenesis (in the case of SCFAs; ref. 393). Intestinal microbes have been
characterized to participate in more than just colorectal carcinogenesis. Experimental models of gut flora also elucidate the development of other extraintestinal cancers, such as hepatocellular
carcinoma (394, 395), presumably through systemically disseminated metabolic networks. Helicobacter pylori (H. pylori) is a Gramnegative bacterial pathogen that selectively colonizes the gastric
epithelium. It is postulated that half of the world’s population is
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infected with H. pylori, although colonization of the pathogenic
bacteria does not cause any symptoms in a majority of the population. Nevertheless, long-term carriage of H. pylori significantly
increases the risk of developing diseases. Among infected individuals, approximately 10% develop peptic ulcer disease, 1% to
3% develop gastric adenocarcinoma, and <0.1% develop mucosaassociated lymphoid tissue (MALT) lymphoma. However, at initial
stages, gastric MALT lymphoma can be cured completely by the
eradication of H. pylori with antibiotics (396).
Apart from antibiotics, probiotics may also inhibit tumorigenesis and cancer progression. Konishi and colleagues (397) reported
that the culture supernatant of L. casei has tumor-suppressive effect on colon cancer cells. The authors reported that ferrichrome
produced by L. casei is the molecule that provides tumor protection and is exerted via the JNK signaling pathway.
The etiology of breast cancer is still not understood, although
it is believed the disease is due to a combination of both genetic and environmental factors. It is posited that environmental factors influence breast cancer, as there is an increased incidence of breast cancer among migrants and their descendants
after they move from a region of low breast cancer risk to a region of high risk. Bacterial communities within the host could be
one such environmental factor that may influence breast cancer development. Different bacterial profiles in breast tissue exist between healthy women and those with breast cancer. Breast
cancer patients had higher levels of Bacillus, Enterobacteriaceae,
and Staphylococcus. E.coli and Staphylococcus epidermidis isolated from breast cancer patients induced DNA double-stranded
breaks in HeLa cells. There was also a decrease in some lactic
acid bacteria, known for their beneficial health effects, including anticarcinogenic properties (398). It has been demonstrated
that women who drink fermented milk products have a reduced
risk of breast cancer development (399). Oral administration of
Lactobacillus species has been shown to be protective in animal
models of breast cancer (400).
Case studies back to the 1700s have recounted the development of bacterial infections in cancer patients that led to remissions of their malignant disease. One of the pioneers in this field,
the U.S. surgeon William B. Coley, engaged in a lifelong study of
this phenomenon after the loss of his very first patient in the late
1800s to a rapidly invasive sarcoma (401). Searching the literature
available, Coley discovered records of another sarcoma patient
with relentless sarcomatous recurrences following surgical resection and an ultimate wound infection (erysipelas) with Streptococcus pyogenes (S. pyogenes) and high fever. To his surprise, after
each attack of fever, the ulcer improved, the sarcoma shrank, and
the lesion ultimately regressed completely. Coley suspected that
in some manner, the infection had induced tumor regression and
began a series of trials to “cure” his cancer patients with pathogen inoculation. He infected his next 10 patients, but observed
intrinsic variability in efficacy using this method (402). Because of
this unpredictability, he elected to create a formulation containing
two killed bacteria: S. pyogenes and Serratia marcescens. Under the
form of an inactivated vaccine, he could simulate an infection (inflammation, chills, fever) without the actual risks of a life-threatening disease. This vaccine became known as ``Coley toxins.’’ The
relative success with Coley’s vaccine was by no means limited to
sarcomas. For decades, this vaccine form had been used by other
contemporaries for carcinomas, lymphomas, melanomas, and myelomas (403, 404).
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Figure 3. Dysbiosis: an immunocompromised state characterized by pathobiont colonization that leads to hyperinflammation, dysplasia, and tumorigenesis. Symbiosis (left): a symbiotic gut microbiota operates under a functional intestinal epithelial cell barrier, with steady-state proportions of
mucus, pattern recognition receptors, antimicrobial peptides, and secretory IgA, which in turn contain the microbiota in the intestinal lumen. Under
tight control by intestinal epithelial cells, the intestinal immune system within the gut lamina propria becomes largely tolerant to the resident commensals. Signaling cascades that occur downstream of TLRs are used by intestinal epithelial cells to detect microbes through pattern recognition receptors. Upon LPS stimulation of TLRs, the MYD88 protein is recruited, activating the NF-kB pathway, leading to production of antimicrobial proteins
and proinflammatory cytokines. In a symbiotic gut, intestinal epithelial cells are desensitized by repeated exposure to LPS or are attenuated by LPSmediated downregulation of the IL1 receptor–associated kinase 1 (IRAK1), an activator of the NF-kB cascade. Exposure to LPS induces epithelial cells
to secrete TGFβ, B-cell–activating factor of the TNF family (BAFF), and a proliferation-inducing ligand (APRIL), all of which promote the development
of tolerogenic responses to the microbiota. CD103+ DCs support the development of Tregs to secrete IL10 and TGFβ, and together, they stimulate
the production of commensal-specific IgA. Dysbiosis (right): increased intestinal exposure of diverse PAMPs, proinflammatory cytokines, apoptotic
debris, and toxins leads to microbial dysbiosis and overgrowth of “pathobionts,” transformed symbiotic bacteria now under pathologic conditions.
Pathobiont overgrowth leads to the loss of barrier integrity and a breach in the intestinal epithelial cell barrier. Translocation of bacteria and bacterial components triggers the intestinal immune system through TLR activation, resulting in potentially harmful effector T-cell responses set to clear
invading bacteria. Ultimately, the secretion of IL1 and IL6 from intestinal epithelial cells fuels a Th1 and Th17 response by DCs and macrophages and
leads to higher levels of commensal-specific IgG by B cells.

However, with the advent of radiotherapy and chemotherapy,
and the empowerment of the FDA in 1964 that restricted clinical
use of “Coley toxins,” the use of microbial toxins in oncology fell
out of use. There were, however, rare instances in which this line
of thinking endured and eventually received FDA approval. Perhaps the most prominent example is the use of Bacillus Calmette–
Guerin (BCG) for the treatment for superficial bladder cancer (405).
BCG is currently the only conventional bacterial vaccine in use
for direct tumor killing. Unlike Coley toxins, BCG is not administered with the ultimate goal of induced fever. But similar to Coley’s methods, the vaccine is applied directly to the tumor site with
repeated courses following initial resection to prevent recurrence

(406). After intravesicular administration of this vaccine, a wide
range of cytokines become detectable in the urine, including IL1,
IL2, IL6, IL8, IL10, IL12, IL18, IFNγ, IFNγ-inducible protein-10, macrophage colony-stimulating factor, and TNFα (407–409). This inflammatory host response illustrates the point that individual immunomodulating cytokines are partial components of a much
more complex immunologic response to infection, and correspondingly, tumor regression. Some insights were gleaned from
Coley toxins and other historical reports on live or attenuated
bacterial inoculations. One was that a local inoculation produces
only a local response. Thus, BCG use is limited to superficial bladder cancer. The heat and immune activation associated with local
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inflammation are perceived to be a minimized febrile response,
and correspondingly, this local response is only effective in the
immediate region where it occurs (401). Since Coley’s passing, the
field of tumor immunology has developed into a better founded
and more sophisticated specialty, with investigators not only employing a variety of basic immunologic principles (e.g., antitumor
cytokines, cytotoxic T cells, immunostimulatory antibodies, cellbased vaccines) but pivotal insights into the dominance of tumoral
immune suppression in blunting the effectiveness of any immunotherapy. Overcoming this historical source of failure in the efficacy
of cancer immunotherapy is empowering this field anew today.
There are more than a hundred chemotherapy drugs to treat
many types of cancers. However, it is not fully understood the
mechanism of some of these drugs. Cyclophosphamide is a clinically important chemotherapeutic cancer drug that stimulates
antitumor immune responses. Viaud and colleagues (410) demonstrated that cyclophosphamide alters the composition of microbiota in the gut and induces the translocation of several Grampositive bacteria into mesenteric lymph nodes and spleen. In the
lymphoid organs, the Gram-positive bacteria stimulated the generation of pathogenic Th17 (pTh17) cells and memory Th1 immune
responses. Germ-free tumor-bearing mice or treated with antibiotics to kill Gram-positive bacteria showed a reduction in T-cell
responses, and their tumors were resistant to cyclophosphamide.
Adoptive transfer of pTh17 cells restored the antitumor efficacy of
cyclophosphamide. Overall, the study suggested that the gut microbiota help shape the anticancer immune response.

Turning the Tables: Using Engineered Microbes
to Attack Cancer
Over the past century, knowledge gained on how selective microbes either facilitate the growth of cancer or alternatively act as
tumoricidal agents permits us open access to utilize this doubleedged sword to our advantage. Such interventions have already
begun and span several modalities, including but not limited to
the use of helper peptide sequences from bacterial subunits, bacterial toxin–fusion proteins, oncolytic viral vaccines, and, as recent
studies elucidate, leveraging the metabolism of host flora to potentiate immune modulators.
Broadly defined, an immunotherapeutic is any modality that
manipulates the immune system for enhanced therapeutic outcome. These include nonspecific activation of the immune system
with microbial components or cytokines, antigen-specific adoptive
immunotherapy with antibodies or lymphocyte transfers, and active immunotherapy by direct vaccination against tumor-specific
proteins, or antigens. We traditionally regard vaccines as educators for the naïve immune system that are administered prophylactically in anticipation of any infection. However, in the setting of
aggressive cancers, the use of cellular vaccines to mount reactive
immune responses is now being employed with promising results.
A variety of cancer vaccines are currently under investigation,
but perhaps the most widely investigated to date are (i) cellular
vaccines composed of APC loaded with tumor antigen (411–414)
and (ii) peptide vaccines (415, 416). Peptide vaccines are comprised of 8–25 amino acids that encompass an epitope, a recognizable sequence coding for an antigen. The transient nature and
low magnitude of responses in many cancer patients has elucidated that tumors themselves are inherently proficient at downplaying immune responses as well as escaping antigen recognition
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altogether. Thus, there is an urgent need for improving vaccine immunogenicity and for ensuring that cancer antigens are sufficiently
immunogenic. To enhance peptide vaccine immunogenicity, these
small peptides are often conjugated to a carrier protein, such as
keyhole limpet hemocyanin (417, 418) and tetanus toxoid (419,
420). These helper proteins enable recognition by and activation
of the immune system with great potency and generate complimentary bystander activation with cytokine release and maturation
of effector cell phenotype. Peptide vaccines are appealing in cancer therapy because they are relatively easy to manufacture and
store, and they do not require laborious preparations. Because of
their “off-the-shelf” feature, repeated boosting for enhanced immune activation also distinguishes peptide cancer vaccines as an
expandable modality (421).
Adoptive immunotherapy has also been utilized to eradicate
established tumors (422). This process involves ex vivo activation
of autologous immune cells, isolated from either peripheral blood
or intratumoral lymphocytes (423, 424), into lymphocyte- activated
killer cells. Lymphocyte-activated killer cells are generated by culturing autologous peripheral lymphocytes with IL2, a vital growth
cytokine for generating T cells and natural killer (NK) cells. These
killer cells are then returned to the patient intratumorally or intravenously, where they become activated by host APCs and exert their tumoricidal effects. Using the knowledge we have gained
from microbial components, NK cells have been potentiated by leveraging the cytolytic capacity of microbial diphtheria toxin. One
study demonstrated that haploidentical NK cells for relapsed and
refractory acute myeloid leukemia could be augmented and improved with a lymphodepletive platform using diphtheria toxin
conjugated to IL2. Using the immunotoxin IL2DT to deplete immunosuppressive Tregs, investigators appreciably improved rates
of in vivo NK-cell expansion (10% vs. 27%) and AML 28-day remission (53% vs. 21%; P = 0.02) compared with the cohort without IL2DT (425).
Oncolytic viruses represent another immunotherapy modality that has gained recent traction in the field of tumor immunology. Use of these microbes was first based on early reports
of spontaneous cancer remissions coincident with natural infection or upon the use of live attenuated vaccines (426). Since then,
an improved understanding of the molecular basis for viral host
cell tropism, cytotoxicity, and cell type specificity has opened up
avenues for the very selective design of virally based anticancer
strategies. To be efficacious and safe, an oncolytic virus must
possess (i) an inherently low human pathogenic potential (i.e.,
the orphan reovirus; ref. 427); (ii) a veterinary pathogen with unknown human pathogenicity (i.e., vesicular stomatitis virus; ref.
428); or (iii) a human pathogen genetically engineered to selectively kill cancerous cells without collateral cytotoxicity in normal cells (i.e., herpes simplex virus-1; ref. 429). One such group
is utilizing a prototype nonpathogenic poliovirus recombinant,
known as PVSRIPO. Poliovirus naturally targets the vast majority
of ectodermal/ neuroectodermal cancers expressing its cellular
receptor, CD155. Evidence from glioblastoma patients suggests
that the CD155 receptor is ectopically upregulated on tumor
cells. Preclinical studies have shown that treatment of glioma
xenografts with intratumoral inoculation of PVS-RIPO produced
rampant tumor cell death, potent host-mediated inflammatory
reactions against infected tumors, and rapid tumor decline (430,
431). The use of PVS-RIPO is now being evaluated in the phase
I setting for recurrent glioblastoma (432).
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Figure 4. Gut microbiome directs the efficacy of immune checkpoint therapy. Both anti-CTLA-4 and anti-PD-L1 therapies rely on gut microbiota for
efficacy in immune activation. Anti-PD-L1 therapy has been shown to rely on the preexistence of sufficient Bifidobacterium species, which are also
thought to augment responses via PD-L1 binding on APCs, such as DCs and macrophages. Subsequent ligation results in the prevention of suppressive signals to PD-1–expressing T cells. Similarly, anti-CTLA-4 indirectly alters the intestinal flora and enriches the Bacteroides species, possibly by
promoting deterioration of the intestinal epithelial cell barrier via activation of local lymphocytes. These bacteria then promote the activation of DCs,
which present tumor antigens to prime and maintain antitumor T-cell responses. Anti-CTLA-4 holds additional activation functions, including (i) preventing CTLA-4 from blocking activation of the costimulatory molecule CD28 on T cells and (ii) blocking the immunosuppressive function of Tregs,
which are required in the deactivation of immune responses against tumors.

As multiple studies are being carried out yearly, investigators
continue to uncover key barriers to efficacy that further clarify our
strategies. As with any antigen-specific immune response, several
homeostatic mechanisms remain at play to prevent rampant damage to the host or autoimmune toxicity. One of the most exciting regulatory axes to be studied recently is that of programmed
death (PD)-1/PD ligand-1 (PD-L1). PD-1 is a coinhibitory receptor
that is inducibly expressed by T and B cells upon activation. Antigen-specific T cells expressing the PD- 1 receptor will engage with
either of its ligands, PD-L1 or PD-L2 expressed on APC, which elicits an inhibitory cascade and subsequent inhibition of TCR-induced

cytokine production and proliferation (433). PDL-1 is expressed in
several other cell types, including tumor cells and some epithelial cells, lymphoid cells, and myeloid cells (434). Another axis involved in regulating self-recognition is that of cytotoxic T lymphocyte antigen-4 (CTLA-4). Studies have demonstrated that tumor
cells stimulate CTLA-4, promoting a cascade of inhibitory immune
processes and ultimate T-cell inactivity against tumors themselves
(435, 436).
In cancer immunotherapy, mAbs against the immune checkpoints CTLA-4, PD-1, and its ligand PD-L1 have demonstrated
high activity in melanoma and other tumors (437). Ipilimumab,
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an anti-CTLA-4 antibody, was the first approved “immune checkpoint inhibitor.” Although the response rate with ipilimumab is
low (less than 20% of patients have objective responses), many of
those positive responses were associated with long-term survival
(438), with similar results in the first- and second-line settings.
Nivolumab and pembrolizumab, both anti-PD-1 inhibitors, have
now also been approved for the treatment of melanoma, with response rates of up to 40% and a demonstrated survival advantage
in phase III trials (434).
Strikingly, recent findings in preclinical models of cancer stress
the importance of intact gut microbiota for effective immune
checkpoint blockade. One recent study found that antitumor effects of CTLA-4 blockade depended on the presence of distinct
Bacteroides species. In both mice and patients, T-cell responses
specific for B. thetaiotaomicron or B. fragilis were associated with
the efficacy of CTLA-4 blockade. Using antibiotic- treated as well
as germ-free mice, tumors lacking these strains did not respond
to CTLA blockade. This deficiency was rescued by B. fragilis gavage, by immunization with B. fragilis polysaccharides, or by adoptive transfer of B. fragilis–specific T cells. Ultimately, fecal microbial
transplantation from humans to mice confirmed that treatment of
melanoma patients with antibodies against CTLA-4 favored the
outgrowth of B. fragilis with anticancer properties (439). A different preclinical study similarly elucidated that mice treated with gut
commensals of Bifidobacterium displayed significantly improved
suppression of melanoma growth in comparison with non- Bifidobacterium–treated counterparts. These observed differences in
spontaneous antitumor immunity were eliminated upon cohousing or after fecal transfer, eluding to the importance of shared
bacterial colonization. Furthermore, administration of the bacteria
to Bifidobacterium-naïve mice with established melanoma significantly enhanced tumor-specific immunity and response to antiPD-L1 mAb therapy (440). Although the mechanisms from both
these studies are not fully understood, they laid the foundation
behind the requirement for an intact microbiome to enact antitumor responses. One key observation from both these studies was
that they employed subcutaneous tumor models, meaning that
intestinal microbiota exerted antitumor immunity in a systemic
fashion. Both studies relied on the presence of CD8+ T cells. Second, both demonstrate that altered DC activation was a responsible intermediate event between the presence of gut microbiota
and provision of checkpoint inhibitors (Fig. 4).

Conclusions

It is humbling to consider how much biomedical research has been
conducted since the molecular biology revolution of the past century without appreciation of the importance of microbiomes in
health and disease. Like all realms of biomedical investigation,
the field of cancer research can no longer ignore the “other half”
of the organism; it must become as familiar with the genetics, biology, physiology, and immunologic effects of host microorganisms as with the hosts themselves. In considering sources of experimental irreproducibility in biomedical publications that have
been suggested recently to be disturbingly high, it seems likely
that natural variations in microbiome infections present in experimental models and vivariums at different sites will provide one
more challenge to the exquisitely difficult problem of how one defines a “molecular mechanism” in disease. More focus on practical
applications (sought by most funding organizations) along with
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empirical explorations once traditional to biology may offer two
paths forward, as, to paraphrase the pragmatic American philosopher Charles S. Peirce, “You know something if you can do something.” How the current obsession with molecular mechanism will
change in the face of the challenge the microbiome poses to preclinical research is unclear. Nevertheless, as the molecular biology revolution continues to wash up on the shores of reductionism this century, it will be impossible not to reembrace the roots
of traditional biological thought, where ecology, evolution, and a
focus on emergent principles in complex organisms can help recenter the pursuit of new knowledge and its applications to improve disease management and healthy lifespans.
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